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Table	1.	Current	quality	status	of	16	pregnancy	tests	purchased	from	several	developing	countries	
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Fig.	1.	Guidance	on	streamlining	quality	of	manufacturing	with	the	contraceptive	logistic	cycle		
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Abstract	
This	paper	describes	the	development	of	a	guidance	document	for	the	procurement	of	
high	quality	self-test	pregnancy	tests,	intended	for	use	in	low	resource	settings.	Pregnancy	tests	
play	a	key	role	in	sexual	and	reproductive	health	by	facilitating	rapid	diagnosis	of	pregnancy	
status,	and	thereby	enabling	appropriate	follow	up	care	inclusive	of	family	planning,	antenatal	
or	abortion	services.	Access	to	pregnancy	tests,	in	terms	of	cost/affordability,	availability,	and	
quality,	is	a	key	factor	required	to	streamline	the	provision	of	reproductive	health	related	
services.	Although	availability	of	pregnancy	tests	has	increased	and	the	cost	has	decreased	over	
time,	there	remains	a	significant	gap	in	regulatory	control	of	the	quality	of	these	tests,	which	
may	lead	to	prevalence	of	spurious	and	counterfeit	pregnancy	tests	in	the	low-income	markets.	
This	paper	focuses	on	the	role	of	pregnancy	tests	in	family	planning	programs,	provides	
preliminary	evidence	for	current	pregnancy	test	quality	gaps,	and	introduces	the	content	area	
covered	by	the	new	guidance	document	that	was	drafted	in	2016.	The	draft	guidance	document			
covers	applicable	international	quality	standards	and	performance	specifications,	which	would	
enable	procurers	to	make	informed	decisions	on	selecting	and	maintaining	high	quality	self-test	
pregnancy	tests	for	improving	family	planning	services	and	beyond.		
	
	
Keywords:	self-test	pregnancy	tests,	quality,	procurement,	standards,	regulatory,	specifications	
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Introduction	
One	of	the	key	criteria	for	family	planning	provision	is	to	rule	out	pregnancy.	The	
combination	of	the	‘pregnancy	checklist’	with	a	self-test	pregnancy	test	can	rule	out	pregnancy	
in	most	cases,	and	is	advocated	for	use	in	low	resource	setting.	The	pregnancy	checklist	is	a	job	
aid	designed	to	rule	out	pregnancy	with	six	simple	criteria	presented	in	a	question	format.	
However,	some	studies	have	demonstrated	a	provider	and	client	preference	for	use	of	
pregnancy	tests	over	a	checklist,	and	the	adoption	of	the	checklist	remains	low	(Comfort,	
Chankova,	Juras,	Hsi,	Peterson,	&	Hathi,	2016; Crossing	the	thin	blue	line,	2016).	Additionally,	
the	checklist	does	not	work	in	ruling	out	pregnancy	in	certain	cases	where	a	pregnancy	test	
does,	particularly	among	women	who	are	on	long	acting	reversible	contraceptives	(LARCs)	and	
those	who	have	missed	their	period.1	Moreover,	recent	evidence	demonstrates	that	lack	of	
access	to	pregnancy	tests	leads	to	denial	of	contraception	services	(Stanback,	Vance,	Asare,	
Kasonde,	Kafulubiti,	Chen	&	Janowitz,	2013;	Crossing	the	thin	blue	line,	2016).	Taking	into	
consideration	the	key	role	of	pregnancy	tests	in	family	planning,	it	makes	public	health	sense	to	
make	these	tests	available	for	family	planning	either	free	of	charge	or	at	a	minimal	cost.				
Although	evidence	regarding	the	availability	and	cost	of	pregnancy	tests	is	emerging,	the	
quality	of	these	tests	remains	largely	unknown.	A	preliminary	internal	analysis	carried	out	at	
Family	Health	International	360	(FHI	360),	an	international	NGO,	to	evaluate	quality	of	
pregnancy	tests	in	low	resource	setting,	illustrates	quality	gaps	suggestive	of	potentially	
spurious	and	counterfeit	products	in	the	market	(personal	communication).	Some	of	the	key	
																																								 																				
1	If	using	highly	sensitive	pregnancy	tests	(limit	of	detection	25	mIU/ml),	pregnancy	can	be	detected	as	early	as	first	
day	of	missed	menses.	If	using	tests	with	lower	sensitivity	(>limit	of	detection	50	mIU/ml),	it	is	recommended	to	
wait	till	about	10	days	after	expected	date	of	menses	(Pregnancy	tests	for	family	planning,	2013).	
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concerns	observed	were	a	lack	of	conformance	with	international	quality	standards,	inadequate	
instructions	to	carry	out	and	interpret	the	results,	and	scarce	to	non-existent	information	on	
analytical	sensitivity	of	the	test.	Based	on	this	analysis,	FHI	360	is	developing	a	document	to	
provide	guidance	on	selecting	high	quality	pregnancy	tests	to	procurers.	This	paper	provides	an	
overview	of	family	planning,	barriers	for	uptake	of	contraception	and	role	of	pregnancy	tests	in	
family	planning,	and	informs	the	reader	on	prevalent	quality	gaps	and	introduces	areas	covered	
by	the	guidance	document,	followed	by	a	description	of	the	harmonization	process	and	
dissemination	plans	of	the	document.		
Significance	of	Family	Planning	for	Global	Health	Outcomes	
Contraception	enables	couples	and	individuals	to	have	control	over	their	sexuality	and	
reproduction,	and	affects	many	other	key	areas	relating	to	health,	education,	women’s	status	in	
society,	economy	and	the	environment.	Ensuring	healthy	timing	and	spacing	of	pregnancies	has	
been	shown	to	reduce	maternal	and	infant	morbidity	and	mortality	rates	(WHO,	2016).	
Reducing	rates	of	unintended	pregnancies	also	reduces	the	need	for	unsafe	abortion	and	its	
associated	sequelae	(WHO,	2016).	In	addition,	access	to	family	planning	can	reduce	rates	of	
adolescent	pregnancies	and	use	of	barrier	methods	can	reduce	transmission	of	sexually	
transmitted	diseases	such	as	HIV/AIDS	(WHO,	2016).		
Most	authorities	categorize	withdrawal	and	periodic	abstinence	as	‘traditional	
contraceptive’	methods’,	and	“products	and	medical	procedures	that	interfere	with	
reproduction	from	sexual	intercourse”	as	‘modern	contraceptive	methods’	(Hubacher	and	
Trussell,	2015;	Westoff	&	Westoff,	2012).	Recent	estimates	demonstrate	that	if	all	women	who	
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wanted	to	avoid	pregnancy	used	a	modern	contraceptive	method,	unintended	pregnancies	
would	drop	by	70%,	and	26	million	abortions	could	be	averted	(Singh,	Darroch	&	Ashford,	
2014).		Family	planning	programs	play	a	dual	role	in	accomplishing	this	goal	by	reducing	unmet	
need2	through	increased	access	to	contraceptive	methods	and	services,	and	by	creating	a	rise	in	
demand2	for	contraception	through	education	and	communication	(Bongaarts,	2014).	
Barriers	to	Use	of	Contraceptives	for	Women	with	Unmet	Need	
Although	universal	access	to	family	planning	has	been	included	in	both	the	Millennium	
Development	Goals	(MDGs)	and	in	the	Sustainable	Development	Goals	(SDGs),	per	estimates	
made	in	2014,	a	staggering	225	million	women	in	developing	countries	who	wanted	to	avoid	
pregnancy	were	not	using	an	effective	contraceptive	method;	this	gap	has	been	demonstrated	
to	have	remained	stagnant	since	(Singh	et	al.,	2014).	According	to	the	United	Nations	
Population	Fund	(UNFPA),	the	majority	of	the	women	with	an	unmet	need	for	family	planning	
live	in	the	69	of	the	poorest	countries	in	the	world	(Family	planning,	2014).		At	the	same	time,	
trends	in	contraceptive	needs	in	developing	countries	indicate	that	the	number	of	women	
wanting	to	avoid	pregnancy	with	the	use	of	modern	methods	of	contraception	was	57%	in	2012	
(Darroch	&	Singh,	2013).	This	report	also	illustrates	that	the	number	of	women	wanting	to	
avoid	pregnancies	in	the	69	poorest	countries	increased	by	36%	from	2003	to	2012,	when	
compared	to	a	10%	increase	for	higher-income	countries.	
																																								 																				
2	Married	women	who	are	fertile	and	do	not	wish	to	become	pregnant	in	the	near	future	are	assumed	to	have	a	
demand	for	contraception.	While	some	of	these	women	practice	contraception,	some	do	not.	The	former	are	
considered	as	‘current	users’	whose	contraception	needs	have	been	met,	and	the	latter	are	considered	as	those	
with	an	‘unmet	need’	for	contraception.	These	definitions	are	expressed	in	the	formula:		
demand=current	use	+	unmet	need	(Bongaarts,	2004)	
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Research	into	non-use	of	contraception	among	women	with	unmet	need	in	low	and	
middle	income	countries	has	demonstrated	that	access	as	a	barrier	is	becoming	less	frequent	
indicating	that	contraceptive	supplies	are	becoming	increasingly	available	(Sedgh	and	Hussain,	
2014;	Westoff	&	Westoff,	2012).	Trends	in	contraception	use	also	demonstrates	a	shift	from	
the	most	effective	method	of	contraception,	sterilization,	towards	modern	injectable	drugs	and	
barrier	methods	(Cottingham,	Germain	&	Hunt,	2012).	Overall,	these	observations	support	
increased	access	to	modern	contraception	globally.	More	often,	non-use	of	contraceptives	is	
attributed	to	infrequent	sexual	activity	and	concerns	over	side	effects	(Sedgh	&	Hussain,	2014;	
Westoff	&	Westoff,	2012).	Based	on	these	findings,	the	major	future	interventions	to	increase	
use	seem	to	be	through	educating	these	populations	on	the	contraceptive	options	available	to	
them,	developing	better	mechanisms	through	which	women	can	switch	methods	based	on	
reproductive	life-cycle	needs,	and	expanding	access	to	a	wider	selection	of	options	inclusive	of	
more	recent	methods	such	as	intra-uterine	devices,	patch,	implantables	and	injectable	forms	of	
contraceptives.	These	require	improved	family	planning	services	and	supplies.	Barriers	to	
providing	these	are	described	below.	
Barriers	to	Quality	Family	Planning	Services	and	Role	of	Pregnancy	Tests	in	Service	Provision	
Although	the	coverage	of	family	planning	services	has	increased	in	many	countries,	
women	are	commonly	denied	services	based	on	six	types	of	medical	barriers:	1)	
contraindications	(e.g.,	headache	as	a	exclusionary	symptom	(not	supported	by	evidence)	in	a	
community	based	distribution	worker’s	oral	contraceptive	checklist)	2)	eligibility	(e.g.,	age	limits	
on	types	of	contraceptives)	3)	process	hurdles	(e.g.	some	programs	may	require	a	women	to	
undergo	a	physical	examination	prior	to	receiving	contraceptives),	4)	service	provider’s	
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qualifications	(e.g.,	requirements	for	specialists	to	prescribe	injectable	contraceptives	when	a	
trained	personnel	can	carry	out	the	procedure)	5)	provider	bias,	and	6)	country	level	
regulations	(e.g.,	restrictions	on	advertising	contraception)	(Shelton,	Jacobstein	&	Angle,	1992).	
One	of	the	main	barriers	for	the	uptake	of	modern	contraceptive	methods	is	the	need	for	a	
woman	to	present	herself	to	family	planning	services	while	menstruating,	to	prove	non-
pregnancy	(Stanback	et.	al,	2013).	Although	the	presence	of	menses	can	help	rule	out	
pregnancy,	this	requirement	often	results	in	denial	of	contraception	to	non-menstruating	
women	until	they	can	return	to	the	clinic	when	they	are	menstruating	(Stanback	et.	al,	2013).	
Without	adequate	family	planning,	these	women	remain	at	risk	of	unintended	pregnancy	in	the	
interim.		This	barrier	stems	from	the	entrenched	belief	that	contraception	can	harm	an	
undiagnosed	pregnancy,	even	though	a	plethora	of	evidence	supports	the	claim	that	neither	
oral,	hormonal	or	spermicidal	contraceptives	increase	congenital	abnormalities	(Bracken,	
Holford,	White	&	Kelsey,	1978;	Simpson,	1985;	Simpson	&	Phillips,	1990).		
Given	these	constraints,	there	are	significant	challenges	to	implementing	the	
interventions	described	above	to	increase	use,	since	women	who	are	denied	service	may	be	
unlikely	to	return	or	seek	counseling	for	advanced	services.	Finding	solutions	to	reduce	service	
denial	is	useful	and	providing	access	to	pregnancy	tests	appears	to	have	promise.	A	study	
carried	out	in	Zambia	to	evaluate	if	access	to	free	pregnancy	testing	reduces	service	denial	in	
family	planning	clinics	demonstrated	that	while	the	baseline	denial	rate	for	intervention	and	
control	were	at	15%	and	17%,	follow	up	denial	rate	for	intervention	and	control	were	4%	and	
17%	respectively	(Stanback	et	al.,	2013).	Another	study	carried	out	in	Nepal,	where	trained	
community	health	volunteers	provided	a	low-cost	pregnancy	test	to	their	communities,	
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demonstrated	empowerment	of	women	to	make	timely	reproductive	health	choices	(Andersen,	
Singh,	Shreshta,	Shah,	Pearson	&	Hessini,	2013).	Similarly,	the	provision	of	free	pregnancy	tests	
to	community	health	workers	in	Madagascar	has	been	demonstrated	to	increase	sales	of	
contraception	to	their	clients	(Comfort,	Chankovas,	Juras,	Hsl,	Peterson	&	Hathi,	2016).	
Additionally,	a	cross-sectional	study	carried	out	in	South	Africa	has	illustrated	that	having	access	
to	self-test	pregnancy	tests	decreases	the	gestational	age	at	the	time	of	presentation	to	both	
antenatal	care	and	abortion	clinics	(Morroni	&	Moodley,	2006).	Given	the	proven	benefits	of	
pregnancy	status	testing	and	its	public	health	impact,	priority	should	be	given	to	making	
pregnancy	tests	either	free	or	at	a	low	cost	to	family	planning	services.		
Advantages	of	Self-Test	Pregnancy	Tests	over	Checklists	
Although	the	reference	standard	for	ruling	out	pregnancy	is	a	urine	pregnancy	test,	due	
to			availability	and	affordability	issues,	in	2004	the	World	Health	Organization	(WHO)	endorsed	
a	simple	‘pregnancy	checklist’	to	rule	out	pregnancy	with	a	reasonable	amount	of	certainty	
(WHO,	2015).	The	pregnancy	checklist	includes	six	criteria	to	rule	out	pregnancy,	and	if	a	
woman	meets	any	of	the	criteria,	a	provider	can	be	reasonably	certain	that	the	woman	is	not	
pregnant.		However,	the	checklist	cannot	always	rule	out	pregnancy:	1)	in	a	woman	who	is	
amenorrheic	(not	menstruating),	either	because	she	has	recently	given	birth	and	is	not	
protected	by	lactational	amenorrhea	method	(LAM)	or	because	she	has	been	using	LARC	
contraception	method	such	as	injectable	progestin,	and	is	returning	late	for	reinjection	and	2)	
in	a	woman	has	missed	her	menses.	Additionally,	the	performance	of	the	checklist	has	been	
shown	to	vary	depending	on	the	study,	with	sensitivity	ranging	from	55-100%	and	specificity	
ranging	from	39-89%	(Tepper,	Marchbanks	&	Curtis,	2013).	There	is	also	evidence	for	provider	
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and	client	preference	for	a	pregnancy	test	over	the	checklist	(Comfort	et	al.,	2016).				Based	on	
these	additional	benefits	pregnancy	tests	offer,	it	makes	public	health	sense	to	provide	access	
to	free	or	low-cost	pregnancy	tests	as	a	complement	to	the	checklist	(Stanback	et	al.,	2013).	
Quality	Challenges	Associated	with	Self-Test	Pregnancy	Tests	
Clearly,	if	the	use	of	self-test	pregnancy	tests	is	to	be	promoted	in	low-	and	middle-	
income	settings,	there	has	to	be	an	assurance	of	their	quality.	In	the	USA,	the	Food	and	Drug	
Administration	(FDA)	requires	a	510(k)3	clearance	of	any	self-test	pregnancy	test	prior	to	
introduction	to	the	market.	Similarly,	for	the	countries	within	the	European	Union	(EU),	a	
notified	body4	carries	out	a	conformity	testing	of	pregnancy	tests	for	CE	marking5.	However,	
even	in	wealthy	countries,	these	quality	assurance	processes	do	not	have	common	definitions	
or	performance	specifications	(Gnoth	&	Johnson,	2014)	contributing	to	marketing	messages	
about	their	sensitivity			that	are	often	not	accurate	(Cole,	Khanllan,	Sutton,	Davies	&	Rayburn,	
2003;	Davlaud,	Ballongue,	Guillem,	Leblanc,	Casellas,	&	Pau,	1993;	Gnoth	&	Johnson,	2014;	
Wilcox,	2001).		Conditions	are	even	worse	in	resource	poor	settings	where	regulatory	standards	
are	often	lacking	for	diagnostics,	and	quality	assessment	of	pregnancy	tests	remains	sparse	to	
non-existent.	Within	this	weak	regulatory	framework,	prevalence	of	spurious	and	counterfeit	
pregnancy	tests	is	highly	likely,	similar	to	pharmaceuticals.	According	to	the	WHO,	25%	of	the	
pharmaceuticals	in	the	developing	world	are	estimated	to	be	counterfeit	(WHO,	2006).	
Counterfeit	and	fake	pharmaceuticals	are	suggested	to	be	a	significant	incentive	in	the	
																																								 																				
3	510(k)	is	a	USFDA	requirement	for	certain	classes	of	medical	devices	to	make	a	premarket	submission	to	
demonstrate	that	the	device	is	as	safe	and	effective	(substantial	equivalence)	as	a	predicate	device.	
4	Notified	body	is	an	entity	that	has	been	assigned	by	a	member	state	of	the	EU	to	determine	if	a	product	to	be	
placed	on	the	EU	market	meets	relevant	European	Directives.		
5	CE	is	the	abbreviation	for	European	Conformity,	and	the	CE	marking	on	a	product	is	the	manufacturer’s	claim	that	
the	product	conforms	with	EU’s	health,	safety	and	environment	legislations/product	directives.	
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developing	world	due	to	“poverty,	high	cost	of	medicines,	lack	of	an	official	supply	chain,	
legislative	lacunae,	easy	accessibility	to	computerized	technology,	ineffective	law	enforcement	
machinery	and	light	penalties”	(Gautam,	Utreja	&	Singal,	2009);	it	is	likely	that	these	same	
factors	hold	true	for	the	diagnostic	sector	as	well.	To	this	end,	a	study	carried	out	by	FHI	360	in	
Mali,	Malawi	and	Kenya	to	assess	access	to	pregnancy	tests,	demonstrated	that	only	68	out	of	
103	tests	had	a	CE	mark	indicating	conformance	with	an	established	quality	assessment	
pathway	(Crossing	the	thin	blue	line,	2016).			
Exploratory	Analysis	of	Prevalent	Status	of	Pregnancy	Tests	in	the	Developing	World	
To	gain	a	preliminary	understanding	of	quality	status	of	pregnancy	tests	in	the	
developing	world,	an	assessment	of	16	pregnancy	tests	collected	over	a	2-year	period	from	a	
mix	of	low-	and	middle-income	countries	in	the	African	region	was	carried	out.	These	were	
purchased	from	pharmacies	as	individually	packaged	items.	Three	normative	regulatory	
documents	representing	US,	European	and	global	standards:	1.	The	US	FDA	510(k)	for	
pregnancy	tests	2.		ISO	13485	and	3.	in	vitro	Diagnostic	Directive	98/79/EC,	were	used	to	
compile	approximately	30	criteria	for	assessment.		Based	on	this	assessment,	some	of	the	key	
strengths	and	weakness	of	the	pregnancy	tests	are	summarized	in	Table	1.	This	analysis	
demonstrated	that	over	50%	of	the	pregnancy	tests	were	not	manufactured	conformant	to	an	
internationally	recognized	quality	standard.		Even	those	that	claimed	to	conform	to	the	widely	
recognized	CE	marking	did	not	demonstrate	a	conformant	quality	seal,	which	suggests	that	they	
are			a	spurious	or	a	counterfeit	product	(Table	1,	section	1.1).	Moreover,	while	a	majority	of	
the	tests	contained	‘instructions	for	use’,	many	still	did	not	have	have	adequate	information	for	
a	client	or	provider	to	carry	out	the	testing	correctly	(Table	1,	section	1.3).	Similar	observations	
Ashini	Fernando	
PUBH	992:	Master’s	Paper	
13	|	P a g e 	
	
were	made	for	the	interpretation	of	results	(Table	1,	section	1.3)	and	information	on	analytical	
performance	of	the	tests	(Table	1,	section	1.4).	These	deficiencies	bring	into	question	the	
quality	of	these	tests	for	testing	pregnancy,	be	it	in	the	context	of	self-testing	or	point	of	care,	
to	improve	the	quality	of	life	of	people	who	could	benefit	from	it	the	most.	The	outcome	from	
this	analysis	confirmed	some	of	the	speculations	of	fake	and	counterfeit	pregnancy	tests	
entering	the	market	in	low	and	middle	-income	countries.	
Table	1:	Current	quality	status	of	16	pregnancy	tests	purchased	from	several	developing	countries	
Quality	Criteria	Being	Evaluated	 %	Conformance	Rate	Among	Self-Test	Pregnancy	
Tests	(N=16)	
1.1	Quality	standards	
Presence	of	an	internationally	recognized	quality	
endorsement	
44%	
From	those	indicating	CE	marking,	those	that	have	a	
conformant	CE	mark	
71%	
1.2	Labeling	
Indication	of	a	manufacturer	and	contact	information	 44%	
Indication	of	a	lot	number	 94%	
Indication	of	date	of	expiry	 94%	
Indication	of	number	of	units/pkg	 50%	
Indication	of	‘do	not	reuse’	 31%	
1.3	Instructions	for	use	and	result	interpretation	
Indication	of	intended	use	 81%	
Indication	of	instructions	for	use	
Indication	of	instructions	for	use	with	schematics	
Indication	of	when	to	read	results	(declared	reading	time)	
Indication	of	a	time	period	beyond	which	results	are	not	
valid	
94%	
88%	
75%	
	
38%	
Indication	of	result	interpretation	with	schematics	
Indication	interpretation	with	all	four	possible	outcomes		
94%	
44%	
1.4	Analytical	performance	information	
Indication	of	analytical	sensitivity	 13%	
Indication	of	analytical	specificity		 0%	
Indication	of	limitations	of	tests	 0%	
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Development	 of	 Guidance	 on	 Quality	 Assurance	 for	 Self-Test	 Pregnancy	 Tests	 in	 the	
Developing	World	
There	is	clearly	a	need	for	improved	guidance	on	assuring	the	quality	of	pregnancy	tests.	
FHI	360,	with	funding	from	United	States	Agency	for	International	Development	(USAID)	and	in	
consultation	with	members	of	the	Reproductive	Health	Supplies	Coalition	(RHSC),	has	prepared	
a	guidance	document	for	procurers	on	selection	of	self-test	pregnancy	tests	that	meet	
established	international	quality	standards.	The	complete	draft	version	of	this	document	is	in	
Annex	1.	We	present	a	summary	here.	
Target	audience	and	focus	area	
This	document	has	been	designed	specifically	for	procurers	of	pregnancy	tests	at	both	
national	and	international	level	in	the	public	and	private	sectors.	Two	of	the	main	procurers	of	
pregnancy	tests	are	USAID	and	Marie	Stopes	International	(MSI).	The	procurement	process	is	
generally	complex	and	involves	multiple	steps,	agencies,	ministries	and	manufacturers	
(Woldeyesus,	Fresle,	Grayston	&	Hogerzell,	1999).	The	WHO	has	proposed	four	strategic	
objectives	for	pharmaceutical	procurement:	“1)	Procure	the	most	cost-effective	drugs	in	the	
right	quantities	2.	Select	reliable	suppliers	of	high-quality	products	3.	Ensure	timely	delivery	4.	
Achieve	the	lowest	possible	total	cost”	(Woldeyesus	et	al.,	1999).	The	focus	of	the	guidance	
document	is	to	addresses	the	second	objective:	‘selection	of	high-quality	products.’	In	many	
low-	and	middle-income	countries,	procurement	officials	have	limited	experience	in	the	
product	selection	process,	as	well	as	limited	or	no	access	to	unbiased	market	information	on	
product	quality	and	manufacturers’	performance	(WHO	Manual	for	procurement	of	diagnostics	
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and	related	laboratory	equipment,	2013).	Even	if/when	product	quality	information	is	available,	
screening	products	and	identifying	and	applying	acceptable	standards	requires	time	and	skill.	
These	challenges	in	procurement,	combined	with	weak	systems	and	inadequate	regulatory	
infrastructure,	can	lead	to	wasting	of	scarce	funding	on	procuring	inferior	products	that	may	
not	meet	the	public	health	objectives.	This	guidance	document	aims	to	provide	procures	the	
necessary	knowledge	in	a	form	that	can	be	easily	integrated	into	a	procurement	logistic	cycle,	
which	are	the	processes	for	selecting,	procuring,	managing	and	using	a	product.	
Overview	of	guidance	document	
Quality	considerations	must	be	addressed	during	all	stages	of	a	product	design	and	
manufacture	process.	To	this	end,	a	pregnancy	test	has	a	‘product	life	cycle’	constituting	of	
several	stages	that	has	been	put	in	place	by	the	manufacturer	to	ensure	the	product	meets	
these	quality	standards	and	customer	expectations	as	shown	in	Figure	1,	along	with	the	
procurement	logistic	cycle	described	above.	Documents	for	assessing	the	quality	of	a	product	
are	generated	directly	from	the	design	and	manufacturing	steps	of	the	product	life	cycle	
process,	as		illustrated	by	the	orange		arrows	in	Figure	1.		
	The	guidance	document	provides	details	on	what	a	procurer	can	request	from	a	
manufacturer/supplier	to	make	an	informed	decision	about	selecting	high	quality	pregnancy	
tests	(figure	1,	black	arrows).	To	provide	procurers	with	information	on	how	to	interpret	this	
documentation,	a	series	of	normative	documents	and	primary	literature	were	used	to	compile	
quality	standards	and	specifications	relevant	to	pregnancy	tests/in	vitro	diagnostics	that	are	
applicable	in	the	US	and	in	the	EU.	As	there	are	many	pregnancy	tests	in	the	international	
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market	that	do	not	meet	the	US	and	EU	quality	standards,	additional	references	to	assess	
compliance	with	other	Stringent	Regulatory	Authorities	(SRAs)	have	also	been	provided.		Since	
there	are	differences	in	the	regulatory	landscape	across	countries,	the	standards	are	
categorized	under	Recommended	Practices	and	Enhanced	Quality	Practices;	while	
‘recommended	practices’	are	strongly	recommended	to	be	incorporated	immediately,	
‘enhanced	quality	practices’	are	recommended	to	make	procurers	aware	of	higher	standards	
being	applicable	in	the	developed	world,	which	could	be	incorporated	with	improvements	to	
regulatory	infrastructure	over	time.		Every	effort	has	been	made	to	make	the	document	
practical	and	actionable	to	procurers;	the	recommendations	have	been	summarized	in	a	
checklist	format	for	ease	of	integration	into	the	contraceptive	logistic	cycle.		
	 In	addition,	FHI	360,	with	funding	from	USAID,	is	also	in	the	process	of	preparing	simple	
work	instructions	for	carrying	out	performance	testing	of	pregnancy	tests,	referred	to	in	the	
diagram	as	‘pre-	and	post-shipment	performance	testing’	(Fig.	1,	thin	green	arrows),	which	
would	allow	countries	to	test	mainly	the	analytical	sensitivity	of	the	test	against	the	
manufacturer’s	specification.	Based	on	the	experience	with	malaria	rapid	diagnostics,	it	is	likely	
that	most	countries	do	not	have	this	capacity	for	independent	testing,	and	this	is	an	area	that	
governments	should	give	priority	to	when	strengthening	regulatory	mechanisms.			
Fig.	1:	Guidance	on	streamlining	quality	of	manufacturing	with	the	contraceptive	logistic	
cycle:		
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		Quality	criteria	for	assessment		
Criteria	on	which	procurement	decisions	are	made	largely	depend	on	various	factors	
including	funders,	funding,	transparency,	country	level	needs	and	infrastructure.	The	
recommended	criteria,	as	outlined	below,	are	broadly	applicable	in	multiple	procurement	
settings.	
1) Quality	systems	requirements	for	manufacturers:	Manufacturers	must	establish	
organizational	structure,	responsibilities,	resources,	procedures	and	processes	to	ensure	
that	their	products	consistently	meet	applicable	quality	standards	and	specification.		
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The	document	recommends	adoption	of	quality	systems	ISO13485	(international)	or	21	
CFR	part	820	(US).	
2) Product	specific	directives:	Product-	or	class-specific	quality	standards	that	are	required	
to	be	incorporated	into	pregnancy	tests	based	on	country	level	classification.	The	
guidance	is	derived	from	the	US	FDA	over-the-counter	human	chorionic	gonadotrophin	
(hCG)	510(k)	directive	and	EU	in	vitro	Diagnostic	Directive	98/79/EC.	
3) Technical	specifications:	These	specifications	are	instrumental	in	assuring	that	the	
pregnancy	test	performs	effectively	as	intended,	and	reduces	the	wastage	across	the	
supply	chain.	Within	this	category,	the	document	discusses	test	format	and	ancillary	
items,	analytical	performance	(sensitivity,	specificity,	accuracy	and	limitations),	shelf-
life,	packaging,	kit	content	and	labeling	requirements.		
Stakeholder	feedback	
Stakeholders	involved	with	review	and	development	of	the	draft	procurement	
guidelines	include	members	of	RHSC,	who	are	involved	in	reproductive	health	procurement	
programs,	or	are	advising	on	quality	and	procurement	standards.	A	subcommittee	was	
developed	to	review	the	draft	and	advise	on	additions	or	revisions	that	were	required.	The	
subcommittee	involves	representatives	from	Abt	Associates,	Management	Sciences	for	Health,	
MSI,	RHSC,	UNICEF,	UNFPA,	USAID	and	WHO.		
Two	stakeholder	meetings	have	been	carried	out	to	date	to	discuss	and	gain	input	on	
the	content	of	the	guidance	document.	During	the	first	round	of	reviews,	feedback	was	
garnered	through	an	open-ended	discussion.	During	the	second	round	of	discussions,	points	
needing	specific	feedback	were	entered	into	a	structured	questionnaire	to	solicit	feedback	and	
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drive	consensus.	Follow-up	discussions	were	carried	out	with	individual	groups	to	gain	clarity	on	
individual	feedback	when	needed.	Although	two	manufacturers	of	pregnancy	tests	were	invited	
to	the	second	meeting,	they	preferred	to	provide	feedback	on	the	document	via	email.	
Dissemination	platform	for	guidance	document	
Dissemination	efforts	will	be	planned	and	intended,	and	adoption	by	procurers	will	be	
assessed	(Kerner,	Rimer	&	Emmons,	2005).	To	this	end,	FHI	360	is	partnering	with	RHSC,	a	
group	that	brings	together	manufacturers/suppliers,	donors,	service	delivery	groups,	
policymakers	and	buyers	for	procurement	of	reproductive	health	needs.	Their	strategy	includes	
increasing	access	to	reproductive	health	supplies	through	increasing	availability	and	access,	
improving	quality	and	overcoming	inequity.	RHSC	already	serves	as	a	platform	for	awareness	
building	around	the	need	for	free	or	low-cost	pregnancy	tests	and	improving	their	quality.	RHSC	
website	will	house	this	guidance	document.	Inclusion	of	translations,	support,	FAQs	and	other	
supplementary	information	is	likely	to	increase	adoption	and	integration.		
It	is	likely	that	some	country	level	procurers	will	have	challenges	with	adopting	the	
guidelines	due	to	lack	of	technical	knowledge,	and	other	program	based	needs.	To	address	
some	of	these	implementation	challenges,	a	website	with	information	on	manufacturer’s	that	
carry	compliant	pregnancy	tests	is	likely	to	be	very	helpful.	
	
Conclusions	
As	a	variety	of	modern	contraceptive	choices	become	available	to	women	globally,	the	
success	of	uptake	and	sustainment	depends	on	the	improvement	of	family	planning	services,	
supplies	and	empowerment	of	women	to	make	informed	choices	regarding	their	reproductive	
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health.	To	this	end,	increased	availability	of	accurate	and	affordable	self-test	pregnancy	tests	
can	help	accomplish	these	goals.	In	order	for	a	pregnancy	self-test	to	work	effectively,	it	should	
meet	certain	performance	criteria,	which	is	built	into	its	design	and	manufacture.	In	the	
absence	of	specifications	for	these	criteria	for	the	developing	world,	there	may	be	spurious	and	
counterfeit	pregnancy	tests	in	the	market.	To	fill	this	gap,	a	new	guidance	document	to	assist	in	
the	procurement	of	quality	pregnancy	tests	has	been	developed	with	input	and	agreement	
from	major	stakeholders	involved	in	procurement	and	family	planning.	The	guidance	is	
harmonized	with	standards	established	by	normative	international	authorities.	The	document	
provides	tools	for	procurers	to	easily	and	practically	incorporate	quality	product	selection	into	
their	workflow.	Dissemination	followed	by	adoption	of	the	documents	by	procurers	is	the	next	
key			step	in	this	process.	In	our	march	towards	achieving	universal	access	to	reproductive	
health	and	rights,	strengthening	the	quality	component	of	supply	chain	management	is	one	of	
many	steps	required	for	the	successful	achievement	of	the	ambitious	reproductive	health	
targets	set	forth	by	the	SDGs.	
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3  Abbreviations 
	
21	CFR		 Title	21	of	the	US	Code	of	Federal	Regulation	
CE	 	 European	Conformity	
cGMP	 	 Current	Good	Manufacturing	Practice	
EC	 	 European	Commission	
EU	 	 European	Union	
US	FDA	 US	Food	and	Drug	Administration	
FIND	 	 Foundation	for	Innovative	New	Diagnostics	
FSH	 	 Follicle	Stimulating	Hormone	
hCG	 	 Human	Chorionic	Gonadotrophin	
IVD	 	 In	Vitro	Diagnostic		
ISO	 	 International	Organization	for	Standardization	
LH	 	 Luteinizing	Hormone	
MRDTs		 Malaria	Rapid	Diagnostics	
NGO	 	 Nongovernmental	Organizations	
POC	 	 Point	of	Care	
RDT	 	 Rapid	Diagnostic	Tests	
SRA	 	 Stringent	Regulatory	Authority		
TSH	 	 Thyroid	Stimulating	Hormone	
WHO		 	 World	Health	Organization	
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4  Glossary (WORK IN PROGRESS) 
The	following	definitions	were	taken	or	adapted	from	the	following	documents:	X,	Y	and	Z.”	
21	CFR	820:	All	medical	device	manufacturers	supplying	medical	devices	to	the	U.S.	are	
required	by	the	USFDA	to	maintain	a	quality	management	system	in	compliance	with	that	
described	in	21	CFR	820.		
510(k):	A	premarket	submission	made	to	US	FDA	to	demonstrate	that	the	device	to	be	
marketed	is	at	least	as	safe	and	effective,	that	is,	substantially	equivalent,	to	a	legally	marketed	
device.	Submitters	must	compare	their	device	to	one	or	more	similarly	legally	marketed	devices	
and	make	and	support	their	substantial	equivalence.	
Accuracy:	Based	on	test	efficiency	and	defined	as	‘True	positive	plus	true	negative	results	
divided	by	the	total	number	of	samples	tested’	(9).	
Antigen:	A	substance	that	causes	the	immune	system	to	produce	antibodies	against	it.	In	
pregnancy	tests,	hCG	is	used	as	the	antigen	for	producing	antibodies	that	are	used	in	tests	to	
diagnose	pregnancy.		
Assay	principle:	Fundamental	concepts	on	the	composition	and	operation	of	the	self-test	
pregnancy	tests.	
Analytical	performance:		Refers	to	the	reliability	and	validity	of	the	hCG	measurement	results	
produced	by	a	self-test	pregnancy	test.	Typical	properties	assessed	are	interferents	and	
accuracy,	as	relevant	to	this	document	(27).	
Authorized	Representative:	A	legal	entity	who	has	been	appointed	by	the	manufacturer	to	
represent	its	interest	in	a	country		
Batch:	Defined	quantity	of	product	manufactured	in	a	single	process	or	series	of	processes	and	therefore	expected	to	be	homogeneous	(49)	(sometimes	used	interchangeably	with	‘Lot’).	
Expiry	Date:	The	date	at	which	the	product	is	no	longer	considered	acceptable	for	use.	
CE	marking:	On	pregnancy	test	packaging,	manufacturer’s	declaration	that	the	product	meets	
the	essential	criteria	of	the	European	Medical	Device	Directive	98/79/EC.	
cGMP	(current	Good	Manufacturing	Practices):	The	component	of	the	quality	assurance	
system	for	US	FDA,	which	ensures	that	products	are	consistently	produced	and	controlled	to	
the	quality	standards	appropriate	to	their	intended	use	and	as	required	by	the	
marketing	authorization.	
Certificate	of	Analysis	(COA):	(to	be	defined)	
Declaration	of	Conformity:		
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Directive	98/79/EC:	Specific	for	safety,	quality	and	performance	of	in	vitro	diagnostic	medical	
devices	(IVDs);	manufacturers	must	meet	criteria	specified	in	the	directive	to	qualify	for	CE	
marking	and	legal	placement	of	an	IVD	on	the	European	Market.		
Diagnostic	performance:	Refers	to	the	capability	of	the	test	to	differentiate	between	pregnancy	
and	non-pregnancy.	Typical	properties	assessed	are	sensitivity	and	specificity,	as	relevant	to	
this	document	(27).	
False-positive	rate:	Percentage	of	all	tests	of	a	particular	product	that	returned	a	positive	result	
when	it	should	not	have,	when	obtained	within	the	manufacturer’s	recommended	reading	time	
(1).		
Human	chorionic	gonadotropin	(hCG):	A	hormone	made	by	the	cells	in	the	placenta	during	
pregnancy	that	is	used	to	monitor	pregnancy	status.	
Intended	use	/	purpose:	The	objective	intent	of	the	manufacturer	regarding	the	use	of	a	
product,	process	or	service	as	reflected	in	the	specifications,	instructions	and	
information	they	provide.	
In	vitro	diagnostic	(IVD)	medical	device:	A	device,	whether	used	alone	or	in	combination,	
intended	by	the	manufacturer	for	the	in	vitro	examination	of	specimens	derived	from	the	
human	body	solely	or	principally	to	provide	information	for	diagnostic,	monitoring	or	
compatibility	purposes	(2).	
Invalid	test:	A	pregnancy	test	in	which	the	control	line	does	not	appear	during	the	result	
reading	period.	(3)	
IVD	medical	device	for	self-testing:	Any	device	intended	by	the	manufacturer	for	use	by	lay	
persons.	
ISO	15523:	Identifies	the	requirements	for	symbols	used	in	medical	device	labeling	that	convey	
information	on	the	safe	and	effective	use	of	devices.	ISO	15523	applies	to	symbols	used	in	a	
broad	spectrum	of	globally	marketed	medical	devices	and	therefore	needs	to	meet	different	
regulatory	requirements.		
ISO	13485:	[year]:	A	quality	management	scheme	created	by	the	ISO	for	medical	device	
manufacturing.	The	standards	prescribe	the	documentation,	procedures	and	structures	that	
must	be	followed	in	all	types	of	organizations	to	facilitate	the	production	of	medical	devices	of	
consistent	standard.	
Manufacturer:	Any	natural	or	legal	person	with	responsibility	for	the	design,	manufacture,	
fabrication,	assembly,	packaging	or	labeling	of	a	medical	device,	for	assembling	a	system,	or	
adapting	a	medical	device	before	it	is	placed	on	the	market	and/or	put	into	service,	regardless	
of	whether	these	operations	are	carried	out	by	that	person	or	on	their	behalf	by	a	third	party	
(4).		
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Notified	body:	An	independent	body	involved	in	the	compliance	assessment	process,	as	
detailed	in	the	European	Union	directives.		
Point-of-care:	Testing	that	is	performed	near	or	at	the	site	of	a	patient	which	may	result	in	a	
possible	change	in	care	of	the	patient	(4)	
Procurement:	The	process	of	acquiring	supplies	from	private	or	public	suppliers	or	through	
purchases	from	manufacturers,	distributors	or	agencies	(3).	
Quality	assurance: Quality	assurance	is	a	wide-ranging	concept	covering	all	matters	that	
individually	or	collectively	influence	the	quality	of	a	product.	It	is	the	totality	of	the	
arrangements	made	with	the	object	of	ensuring	that	products	are	of	the	quality	required	for	
their	intended	use]	
Registration:	Any	statutory	system	of	approval	required	at	national	level	as	a	precondition	for	
introducing	a	product	in	the	market	(3)	
Self-testing:	Testing	[examination	to	align	with	labelling	standard]	performed	by	lay	persons.	
Shelf-life:	Period	of	time	until	the	expiry	date	during	which	an	IVD	device/reagent	in	its	original	
packaging	maintains	its	stability	under	the	storage	conditions	specified	by	the	manufacturer	(4).	
Stability:	Ability	of	an	IVD	to	maintain	its	performance	characteristics	within	the	limits	specified	
by	the	manufacturer	(4).	
Stability	testing:	Long-term	accelerated	(and	intermediate)	studies	undertaken	on	batches	
per	a	prescribed	protocol	to	establish	or	confirm	the	re-test	period	(or	shelf-life)	of	a	
product.	
Specification:	ALT	DEF:	a	statement	of	the	procurer’s	requirements	and	covers	all	product	
attributes	necessary	for	acceptance.	For	procurement,	the	purchaser	must	provide	a	
specification	that	details	the	characteristics	and	quality	of	the	product	to	be	manufactured.	
These	include	essential	general	and	performance	requirements	as	well	as	discretionary	design	
requirements.		
Stringent	Regulatory	Authority	(SRA):	The	national	drug	regulatory	authorities	who	are	
members,	observers	or	associates	of	the	International	Conference	on	Harmonisation	of	
Technical	Requirements	for	Registration	of	Pharmaceuticals	for	Human	Use	(ICH).		
	
Standards:	Standards	are	published	by	national,	regional	and	international	standard	bodies	to	
establish	the	minimum	performance,	quality	and	safety	requirements	for	products	that	are	
made,	imported	and	sold	within	a	particular	country	or	region.	They	are	usually	generic	in	
nature	and	not	design	restrictive.	Standards	also	specify	standardized	test	methods	to	be	
used	when	testing	products	for	quality	assurance	and	conformance	purposes	
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5  Background 
	
Ensuring	access	 to	 low-cost,	high	quality,	 self-test	pregnancy	 tests	has	been	 shown	 to	
increase	same-day	provision	of	family	planning,	and	aid	in	the	timely	provision	of	antenatal	care	
(5-8).	 However,	 in	many	 settings,	 pregnancy	 tests	 are	 not	 routinely	 available	 for	 clients,	 are	
marked	 up	 to	 unaffordable	 prices	 and/or	 are	 of	 questionable	 quality.	 In	 2015,	 FHI	 360	
partnered	with	Marie	Stopes	International	to	conduct	an	assessment	in	three	countries	(Kenya,	
Malawi	 and	Mali)	 to	 document	 availability,	 affordability	 and	 quality	 of	 pregnancy	 tests.	 This	
project	was	completed	with	support	from	the	Reproductive	Health	Supplies	Coalition	through	
an	Innovation	Fund	grant.		
Key	findings	from	the	assessment	included	that	there	were:			
• Concerns	about	fake	and	counterfeit	products	or	suspect	CE-marked	pregnancy	tests	
entering	markets;	
• A	lack	of	knowledge	among	consumers,	providers,	importers,	distributors,	pharmacists	
and	regulatory	personnel	on	internationally	recognized	quality	standards	for	pregnancy	
tests	including	what	existing	standards	mean	and	how	they	can	be	used	to	ensure	that	
only	quality	pregnancy	tests	enter	national	markets;		
• No	publicly	available	protocol	for	pre-and	post-shipment	testing	of	pregnancy	tests;		
• Limited	visibility	for	procurers	on	the	supply	side	(e.g.,	limited	information	about	
suppliers’	prior	performance);	
• A	lack	of	coordination,	focus	and	harmonization	around	pregnancy	test	procurement	
guidelines.		
	
In	addition,	FHI	360	carried	out	an	exploratory	evaluation	of	a	small	number	of	
pregnancy	tests,	collected	from	developing	countries	over	a	two-year	period,	to	develop	an	
understanding	of	prevailing	quality	status.		The	preliminary	results	from	this	analysis,	as	
summarized	in	Annex	S1,	illustrates	significant	quality	gaps	in	terms	of	conformance	with	
international	quality	standards	and	technical	performance	criteria.		
	
Given	the	lack	of	regulatory	oversight	for	diagnostics	in	many	countries,	assessment	by	a	
more	stringent	regulatory	authority	(SRA)	is	often	used	as	an	alternative	or	complementary	
strategy	for	national	approval	or	for	ensuring	international	quality	standards.	Global	efforts	
towards	harmonization	of	regulatory	approaches	have	led	to	internationally	accepted	standards	
for	a	risk-based	approach	for	the	pre-market	assessment	of	safety,	quality	and	performance	of	
diagnostics	–	these	include	a	number	of	SRAs	tha
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Harmonization	Task	Force	-i.e.,	European	Union	(EU),	US	Food	and	Drug	Administration	(US	
FDA)	and	other	SRAs	(Annex	S2).	
	
In	 2016,	 with	 support	 from	 the	 USAID-funded	 Envision	 FP	 project	 led	 by	 FHI	 360,	 this	
document	was	developed	to	address	some	of	these	gaps	in	knowledge	and	practice	by	outlining	
requirements	 for	 quality	 standards	 and	 providing	 details	 on	 technical	 specifications,	 derived	
mainly	from	the	EU,	US	FDA	and	ISO	13485,	to	inform	pregnancy	test	procurement	and	related	
decision-making.	
Developed	in	consultation	with	key	stakeholder	groups	and	in	alignment	with	WHO	and	
FIND’s	 initiatives	 towards	 the	 improvements	 of	 quality	 of	malaria	 rapid	 diagnostics	 (MRDTs),	
this	document	 identifies	global	 standards,	 technical	 specifications	encompassing	performance	
criteria	and	best	practices	in	an	effort	to	increase	access	to	high	quality	pregnancy	tests	in	low-
resource	settings.		
	
6  Intended Audience 
	 	
This	document	has	been	designed	to	provide	knowledge	and	guidance	to	procurers	to	
understand	the	relevant	manufacturing	and	product	quality	standards	that	apply	to	pregnancy	
tests,	and	to	develop	adequate	specifications	for	their	procurement	related	decision	making.	
Its	intended	audience	includes	individuals	responsible	for	the	procurement,	supply,	and	
quality	assurance	of	pregnancy	tests	at	a	global,	national	and/or	local	level	including	
procurement	officers,	health	officers	and	supply	chain	managers	responsible	for	selecting,	
procuring	or	assisting	in	the	procurement	of	pregnancy	tests	for	use	in	the	public	and	private	
sectors.	In	addition,	the	document	is	relevant	to	those	manufacturers	who	wish	to	supply	
pregnancy	tests	to	global	and	local	public	health	programs.	This	document	may	also	prove	
helpful	to	policy	makers	and	social	marketing	and	service	delivery	groups.				
	
7  How to Use this Document 
	 	
Broadly,	this	document	provides	recommendations	on	quality	standards	(section	10)	and	
technical	specifications	(section	11)	for	self-test	pregnancy	tests.		The	areas	covered	are	those	
derived	from	ISO	13485,	US	FDA	and	EU	CE-marking,	and	are	outlined	in	Figure	1.	References	
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have	been	provided	for	other	SRAs	as	pertinent	to	the	rest	of	the	world	(ROW)	quality	
standards	(Annex	S2).		
Figure	1:	Areas	of	guidance	covered	in	this	document	
				
Ø In	developing	this	document,	careful	consideration	was	given	to	the	unique	
challenges	in	resource-poor	settings	through	a	consensus	driven	process,	and	the	
recommendations	discussed	within	the	main	text	of	the	body	was	considered	as	
adoptable	by	most	countries,	regardless	of	the	level	of	maturity	of	regulatory	
infrastructure.	In	addition,	at	the	end	of	each	quality	criteria,	‘enhanced	quality	
practices’	have	been	included	in	green	boxes	for	consideration	by	those	countries	
with	more	mature	regulatory	infrastructure;	this	information	is	also	useful	for	
awareness	building	within	the	community	about	additional	quality	practices	that	
could	bring	about	even	better	outcomes.	
Enhanced	quality	practices	
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Ø At	the	end	of	quality	criteria	sections,	where	applicable,	documents	procurers	are	
recommended	to	request	from	manufacturers	are	summarized	in	orange	boxes.	
	
	
Ø In	Annex	S3,		all	the	relevant	details	of	the	document	have	been	categorized	and	
summarized	in	a	checklist	form	for	procurers	to	incorporate	into	their	workflow.	
Ø Detailed	annexes	on	several	pertinent	areas,	have	also	been	provided	for	those	
wanting	more	information.	
Ø Blue	call-out	boxes	have	been	used	to	highlight	further	clarifications.	
	
	
Ø This	document	is	not	intended	to	replace	existing	guidance	on	procurement	
processes,	but	rather	to	provide	quality	related	technical	guidance	specifically	
related	to	the	selection	of	self-test	pregnancy	tests	for	procurement.		
o For	recommended	guidance	on	procurement	processes	and	supply	chain	
management	please	refer	to	Annex	S4	for	a	recommended	reading	list.		
o For	information	on	Contraceptive	Logistics	Cycle	and	measures	for	
monitoring	and	quality	improvement	please	refer	to	Annex	S5.		
	
Technical	and	quality	assurance	experts	with	specific	insight	into	the	procurement	of	
health	commodities-in	particular	rapid	diagnostic	tests—are	recommended	to	be	involved	in	
both	the	selection	and	continuous	quality	monitoring	of	pregnancy	tests	procurement	process.	
	
Should	you	have	any	questions,	please	contact	us	at:	EnvisionFP@fhi360.org	
This	document	will	be	housed	in	the	following	websites	for	free	access:	
Ø 	
	
	
8  Applicability of Guidance 
	
	 The	standards	and	specifications	described	herein	are	applicable	to	three	formats	of	
self-test	pregnancy	tests	that	are	designed	to	use	urine	as	sample,	and	can	be	read	visually	
																					Documents	for	procurers	
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without	the	aid	of	an	additional	device:	1)	dipstick,	2)	cassette-type,	or	3)	midstream	(Figure	2).	
This	guidance	document	does	not	apply	to	blood	tests	that	evaluate	pregnancy	status.	
	
	
Figure	2:	Three	formats	of	self-test	pregnancy	tests	covered	in	this	document	
	
9  Overview of Self-Test Pregnancy Tests 
	
	 Self-test	pregnancy	tests	are	also	known	as	‘urine	pregnancy	tests,’	‘home	pregnancy	
tests,’	‘hCG/HCG	tests,’	and	‘over-the-counter	pregnancy	tests’;	the	term	‘point-of-care	
pregnancy	tests’	is	often	used	when	the	test	is	run	by	the	provider.	Typical	self-test	pregnancy	
tests	are	designed	to	provide	a	qualitative	result	indicating	only	a	negative	or	positive	result	
(yes/no	result).	
The	most	common	tests	come	in	three	formats	as	illustrated	in	Figure	2:	dipstick,	
cassette	and	midstream	format.	The	principle	behind	this	diagnosis	is	schematically	described	in	
Annex	S6.	Briefly,	a	dipstick	is	assembled	by	careful	layering	of	different	membranes	on	a	
plastic	backing.	Encasement	of	this	dipstick	in	different	plastic	housing	yields	a	cassette	or	one	
of	the	midstream	formats.	Assay	reagents	constituting	various	antibody	preparations	are	then	
deposited	on	the	test	strip	in	specific	regions.	Upon	addition	of	the	urine	sample,	labeled	
antibodies	are	directionally	mobilized	through	capillary	action.	The	presence	of	the	pregnancy	
hormone,	human	chorionic	gonadotrophin	(hCG),	leads	to	localization	of	the	labeled	antibody	
to	the	test	line	yielding	a	positive	signal.		The	localization	of	labeled	antibody	to	the	control	line	
is	independent	of	hCG,	and	should	yield	a	positive	signal	validating	that	the	assay	and	the	
reagents	are	operating	as	expected.	If	the	test	is	positive	for	pregnancy,	then	the	test	and	
control	line	should	develop;	if	the	test	is	negative	for	pregnancy,	then	only	the	control	line	
should	develop.		
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Approximately	6-12	days	after	fertilization	of	an	egg,	the	woman’s	body	begins	to	
produce	the	hCG	hormone;	hCG	levels	continue	to	rise	as	the	pregnancy	progresses	and	
plateaus	around	45	days	post-conception.	Ninety-eight	percent	of	women	who	have	conceived	
have	a	urine	concentration	of	hCG	>	25	mIU/mL	by	the	day	of	their	next	expected	period	().	Due	
to	natural	fluctuations	in	menstrual	cycles	and	quality	issues	with	pregnancy	tests,	pregnancy	
diagnosis	prior	to	a	week	or	two	after	the	missed	period	remains	challenging.6	
Providers	can	be	reasonably	sure	a	woman	is	pregnant	before	a	missed	period	by	using	the	
Pregnancy	Checklist,	which	has	been	endorsed	by	the	WHO,	USAID	and	a	number	of	country	
governments.	The	Pregnancy	Checklist	and	pregnancy	tests	are	complimentary	tools	as	there	
are	times	when	both	tools	will	not	be	effective	at	ruling	out	pregnancy.	More	information	about	
the	Checklist	is	available	in	Annex	S7.				
 
10     Quality Standards 
	
This	document	briefly	discusses	quality	standards	applicable	to	in	vitro	diagnostics	as	
detailed	out	in	ISO	13485,	US	FDA	and	CE-marking	directives.	The	demonstration	of	compliance	
to	these	quality	standards	involves	a	choice	of	testing	pathways	that	is	dependent	on	the	
classification	of	the	medical	device.	Based	on	perceived	risk	associated	with	the	device	to	the	
user,	US	FDA	has	classified	self-test	pregnancy	test	as	a	Class	II	device	(medium	risk),	while	the	
EU	has	classified	it	as	a	self-test	under	Class	I	devices	(low	risk).		The	conformance	criteria	
relevant	to	self-test	pregnancy	tests	are	discussed	below	based	on	their	applicability	to	
manufacturer	(party	taking	responsibility	for	compliance)	and	product.	
	
 Standards Applicable to Manufacturer  10.1
 
The	manufacturing	site	is	recommended	to	be	in	compliance	with	the	quality	
management	system	regulation	standard	ISO	13485:2003	and	later	7,	which	is	a	globally	
recognized	system	in	many	countries,	or	21	CFR	part	820	cGMP/QSR,	which	is	the	US	FDA	
requirement	for	medical	devices.	A	well	established	and	compliant	quality	management	system	
is	instrumental	to	manufacturing	of	high	quality	pregnancy	tests.	
																																								 																				
6	If	using	highly	sensitive	pregnancy	tests	(limit	of	detection	25	mIU/ml),	pregnancy	can	be	detected	as	early	as	first	
day	of	missed	menses.	If	using	tests	with	lower	sensitivity	(>limit	of	detection	50	mIU/ml),	it	is	recommended	to	
wait	till	about	10	days	after	expected	date	of	menses	(Pregnancy	tests	for	family	planning,	2013).	
7	ISO	13485:	2003	will	be	valid	until	2019	followed	by	ISO	13485:2016.	
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	Documents	for	Procurers:	It	is	recommended	that	the	procurer	requests	a	copy	of	the	
manufacturer’s	ISO	13485	certification	at	the	time	of	assessment.	The	validity	of	the	
certificate	can	be	checked	by	consulting	the	body	that	issued	it,	and	it	is	recommended	that	
the	renewal	date	be	added	to	the	supplier’s	records.	It	is	important	that	the	scope	of	the	ISO	
13485	certificate	is	checked	so	that	the	production	of	the	pregnancy	tests	fall	within	the	
issuance	of	the	certificate.	
	
Ø The	industry	standard	for	overall	quality	management,	ISO	9001,	should	not	be	confused	
with	the	quality	system	standard	ISO	13485:2003.	Proof	of	compliance	with	ISO	9001	
alone,	as	commonly	seen	with	self-test	pregnancy	tests,	is	not	adequate	for	compliance	
with	ISO	13485.	
ISO	9001:	This	standard	sets	out	the	requirements	for	a	quality	management	system.	It	
helps	businesses	and	organizations	to	be	more	efficient	and	improve	customer	
satisfaction	(22).	
ISO	13485:	This	quality	management	system	standard	sets	requirements	for	an	
organization	to	demonstrate	its	ability	to	provide	medical	devices	and	related	services	
that	consistently	meet	customer-	and	regulatory-requirements.		All	requirements	of	ISO	
13485:2003	are	specific	to	organizations	providing	medical	devices,	regardless	of	the	
type	or	size	of	the	organization	(23).	This	standard	is	required	as	the	basis	for	quality	
assurance	management	of	in	vitro	diagnostic	devices	for	their	registration	and	regulatory	
control	in	many	places.	
	
	
 Standards Applicable to Products 10.2
 
The	pregnancy	test	is	recommended	to	carry	the	CE	marking	as	per	in	vitro	Diagnostic	
Directive	(IVDD)	98/79/EC	for	EU	(Annex	S8),	or	be	US	FDA-approved	as	per	510(k)	(9,10).	
Approval	from	other	SRAs	could	also	be	considered,	subject	to	procurer’s	understanding	and	
knowledge	of	these	groups.	Annex	S2	provides	a	list	of	SRAs	with	links	to	their	websites.	
	
 CE Marking 10.2.1
	
Ø IVDD	98/79/EC	provides	regulatory	requirements	for	obtaining	the	CE	marking.		
Ø Since	pregnancy	tests	belong	to	the”	self-test”	classification,	the	conformance	
process	requires	involvement	of	a	Notified	Body	
Ø The	CE	marking	should	be	in	compliance	with	the	schematics	indicated	in	Figure	3	
and	elaborated	in	Annex	S8,	and	must	be	accompanied	by	the	identification	number	
of	the	Notified	Body	(usually	a	4-digit	number).	CE	marking	and	Notified	Body	
identification	number	must	appear	on	the	device	(if	practicable),	on	primary	and	
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secondary	packaging,	and	in	the	product	insert.	Avoid	selection	of	products	carrying	
nonconforming	CE	marking,	as	indicated	below	in	Figure.	3	(11).		
	
	
Figure	3.	Comparison	of	CE	marking	of	conformity	and	nonconformity	
	
	
Ø The	manufacturer	is	recommended	to	draw	up	the	Declaration	of	Conformity	(DoC)	to	
declare	sole	responsibility	for	the	conformity	to	the	relevant	directive.	The	DoC	should	
detail	out	manufacturer’s	name	and	address,	essential	characteristics	of	the	product,	the	
identification	number	of	the	Notified	Body,	as	well	as	a	legally	binding	signature	on	behalf	
of	the	organization.		The	DoC	is	recommended	to	be	made	available	to	the	procurers	at	the	
time	of	tender	or	supplier	selection.	
	
Documents	for	Procurers:	It	is	recommended	that	the	procurer	request	a	copy	of	CE	
Declaration	of	Conformity	from	the	manufacturer	at	the	time	of	assessment.		
	
	
 US FDA approval/510(k) clearance 10.2.2
	
A	manufacturer	who	intends	to	market	a	self-test	pregnancy	test	in	the	U.S.	is	required	
to	submit	a	510(k)	application,	also	known	as	a	Premarket	Notification	(PMN).	For	this	process,	
the	manufacturer	must	provide	evidence	demonstrating	that	the	device	to	be	marketed	is	at	
least	as	safe	and	effective	as	a	legally	marketed/predicate	device.		This	process	is	known	as	
demonstration	of	‘substantial	equivalence’	(30).		Once	the	manufacturer	receives	written	
notification	of	FDA	clearance	confirming	‘substantial	equivalence’	to	a	legally	marketed	
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product,	the	test	can	be	marketed	in	the	U.S.	Please	note	that	the	FDA	clearance	is	not	
indicated	on	the	package	labeling.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Documents	for	Procurers	on	US	FDA	Approval:	Check	for	510(k)	clearance	on	the	
US	FDA	website,	and	confirm	with	manufacturer	that	the	same	quality	standards	
have	been	applied	to	the	manufacturing	process	for	pregnancy	test	being	evaluated.		
	
 Rest of the World Regulatory Approvals and Country 10.3
Registrations  
	
For	some	markets,	ISO	13485	is	not	sufficient	for	the	regulatory	approval	of	medical	
devices,	and	an	appropriate	regulatory	certification	issued	by	the	National	Regulatory	Authority	
(NRA)	may	also	be	required.	However,	in	a	number	of	countries,	regulations	applicable	to	
diagnostics	are	generally	weak	to	non-existent.		Therefore,	given	the	lack	of	regulatory	
oversight	for	diagnostics	in	many	countries,	an	assessment	by	a	SRA	is	often	used	as	an	
alternative	or	complementary	strategy	for	national	approval.	Global	efforts	towards	
harmonization	of	regulatory	approaches	have	led	to	internationally	accepted	standards	for	a	
risk-based	approach	for	the	pre-market	assessment	of	safety,	quality	and	performance	of	
diagnostics	–	these	include	a	number	of	SRAs	that	are	founding	members	of	the	Global	
Harmonization	Task	Force	-i.e.,	EU,	US	FDA	and	other	SRAs	(Annex	S2)	(31).	
While	a	number	of	regulatory	agencies	in	developing	countries	have	not	yet	established	
regulatory	requirements	for	medical	devices,	including	IVDs	such	as	pregnancy	tests,	many	are	
510(k)	clearance	is	required	only	for	pregnancy	tests	intended	for	sale	in	the	US	market.	For	
international	procurers	of	pregnancy	tests	considering	products	claiming	to	be	US	FDA-
approved,	it	is	highly	recommended	to:		
1) confirm	that	the	manufacturer	holds	510(k)	clearance	by	visiting	the	510(k)	
premarket	notification	site;		
(US	FDA	home	page	à	Medical	Devices	Tab	à	Medical	Device	Database	(under	
Tools	&	Resources)	à	select	the	‘Premarket	Notifications	(510(k)’	database	àtype	
‘LCX’	under	‘product	code’	à	Search	for	the	product	of	interest)	
Please	refer	to	Annex	S9	for	a	screenshot	of	the	FDA	website	to	check	for	the	510(k)	
clearance	status	of	the	pregnancy	test.	
2)	confirm	with	the	manufacturer	that	the	test	of	interest	is	manufactured	to	the	same	
standard	as	that	cleared	for	the	US	market.	
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in	the	process	of	developing	these	guidelines.		The	landscape	is	changing	rapidly	and	different	
NRAs	will	have	different	requirements.	Prior	to	purchasing	pregnancy	tests	for	specific	markets,	
procurers	are	advised	to	check	the	regulatory	requirements	of	the	country	in	question.	The	
Contraceptive	Technology	Innovation	(CTI)	Exchange	is	a	useful	website	with	links	to	a	number	
of	regulatory	agencies	and	regulatory	information.		
Pregnancy	Tests	may	be	approved	in	the	country	of	origin/manufacture	either	‘for	sale	and	
use	in	the	country	of	origin’	or	‘for	export	only’.	Given	the	differences	in	regulatory	
requirements,	manufacturers	will	often	supply	different	regulatory	versions	of	the	‘same	
diagnostic’	versions	for	markets	with	stringent	regulatory	controls,	and	versions	for	markets	
with	little	or	no	regulatory	control,	often	referred	to	as	‘rest	of	the	world’	regulatory	versions.		
Therefore,	though	a	manufacturer	may	manufacture	a	stringent	regulated	version	of	the	
product,	they	may	equally	supply	a	less-regulated	or	un-regulated	version	of	the	same	product	
without	any	assurance	that	the	same	quality	controlled	components	and	procedures	were	used	
to	manufacture	the	product.	Usually	regulatory	requirements	for	‘export	only’	products	are	less	
stringent	than	those	‘for	sale	and	use.’	Approval	for	‘export	only’	generally	does	not	provide	
sufficient	evidence	of	regulatory	review	of	safety,	quality	and	performance	().	It	is	therefore	
crucial	that	procurers	request	supportive	documentation	to	verify	the	exact	regulatory	status	of	
the	product	to	be	procured.	
	
Documents	for	Procurers	on	other	Regulatory	Approvals:		
Ø It	is	recommended	that	procurers	check	the	regulatory	requirements	of	the	
country	in	question,	prior	to	purchasing	pregnancy	tests.			
Ø For	pregnancy	tests	that	have	been	approved	by	other	SRAs,	it	is	recommended	that	
procurers	verify	regulatory	statutes	applicable	to	the	pregnancy	test	being	evaluated.		
	
11     Technical Specifications 
	
Technical	specifications	are	instrumental	in	the	decision-making	process	involving	
identification	of	effective	pregnancy	tests	that	will	meet	programmatic	needs.	For	example,	it	
would	be	helpful	to	know	the	analytical	sensitivity	of	a	pregnancy	test	so	that	service	providers	
have	a	handle	on	capability	of	the	test	to	diagnose	early	pregnancy.	This	information	is	usually	
included	in	the	Certificate	of	Analysis	(COA),	product	insert,	Technical	File	and/or	on	product	
labels,	as	applicable.		Many	of	the	recommended	criteria	in	this	section	are	based	on	the	WHO	
and	FIND’s	efforts	to	standardize	and	harmonize	malaria	rapid	diagnostic	tests	(MRDTs),	which	
follows	the	same	assay	principle	as	pregnancy	tests.		
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	 Prior	to	selecting	pregnancy	tests	for	procurement,	it	is	recommended	that	procurers	
request	a	dossier	of	technical	product	information	(Technical	Files)	from	the	manufacturer.		
This	dossier	provides	product	specifications,	including	detailed	information	for	each	of	the	
following	technical	categories,	evidence	that	supports	performance	studies,	and	a	copy	of	the	
COA	for	recent	batches.	
	
	
 Test Format and Ancillary Items 11.1
	
The	three	pregnancy	test	formats	operate	slightly	differently	in	terms	of	sample	
application,	and	therefore,	additional	components	are	required	to	carry	out	the	testing.	The	
sections	below	discuss	these	requirements	and	testing	methods	as	applicable	to	each	format.		
	
 11.1.1  Compo nents  of  a pregnanc y tes t
	
Pregnancy	tests	usually	come	in	three	formats:	cassette-type,	dipsticks	or	midstream	test	strips.	
Note	that	ancillary	items	such	as	the	droppers	and	the	urine	collection	cup,	as	shown	in	Figure	
4,	may	not	be	included	with	the	tests.	Therefore,	the	procurer	is	recommended	to	determine	
the	need	for	these	items	and	include	them	in	the	requirements	of	the	tender,	as	appropriate.	
Figure	4.	Example	of	the	three	pregnancy	test	formats	and	their	usage8	
A. Example	of	cassette	with	a	well	for	
urine	sample		
	 	
	 	
	
	
	
	
	
	
	D	 	
Cassette	
The	strip	is	encased	in	a	plastic	cassette.	Key	
features	are:	control	line	(C),	test	line	(T)	and	
a	sample-well	indicating	where	urine	sample	
is	to	be	added	(S)		
	
Ancillary	item	
Dropper	(D),	clean	cup/tube	
	
How	test	is	to	be	used:		Collect	urine	in	a	
clean	cup/tube	à	Using	the	dropper,	
transfer	a	specified	volume	of	urine	into	the	
sample-well,	placed	on	a	flat	surface	with	
result	window	facing	up	à	Read	results	after	
																																								 																				
8	Diagrams	have	been	adapted	from	Malaria rapid diagnostic test performance: Results of WHO product testing of malaria 
RDTs: Round 6 (2014-2015). (n.d.). Retrieved August 31, 2016, from 
http://www.who.int/malaria/publications/atoz/9789241510035/en	
Result	window 
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the	specified	period	of	time.	
	
Ø Based	on	programmatic	point	of	care	
needs,	a	space	on	the	cassette	to	write	patient	
identification	information,	date	and	test	
number	are	recommended.	
	
B. Example	of	dipstick	
	
	
	
	
Dipstick		
The	strip	is	mounted	on	a	laminated	strip.	
Key	features	are:	control	line	(C),	test	line	(T),	
and	absorbent	pad	to	wick	the	urine	(A)	
	
Ancillary	item	
	a	clean	cup/tube	for	urine	collection	(V)	
	
How	test	is	to	be	used:	Collect	urine	in	a	
clean	cup/tube	à	Dip	the	dipstick	in	urine	up	
to	the	line	indicated	by	arrows	(A)	for	the	
specified	period	of	time	à		Place	the	dipstick	
flat	on	a	surface,	with	the	result	window	
facing	up,	for	the	specified	period	of	time	for	
results	to	develop	
C. Example	of	a	midstream	test	strip	
	
	
	
	
	
Midstream	test	strip	
i)	This	format	is	essentially	identical	to	the	
dipstick	format,	but	has	a	longer	absorbent	
pad	to	enable	positioning	of	it	directly	in	the	
urine	stream.	Key	features	are:	control	line	
(C),	test	line	(T),	and	longer	absorbent	pad	to	
directly	hold	in	the	urine	stream	(A).			
	
ii)	Alternative	format	of	midstream	test	
where	the	dipstick	in	encased	in	plastic.	
Encasing	prevents	the	urine	from	wetting	
areas	other	than	that	intended	to	capture	
and	absorb	urine.	
	
How	test	is	to	be	used:	Hold	the	absorbent	
tip	(A)	in	urine	stream	for	the	specified	
period	of	time	à	Place	the	dipstick	flat	on	a	
surface,	with	the	result	window	facing	up,	for	
a	specified	period	of	time	for	results	to	
develop	
	
C 
T 
A 
Result	window 
V 
C T 
A 
Result	window 
i) 
ii) 
Ashini	Fernando	
PUBH	992:	Master’s	Paper	
46	|	P a g e 	
	
	
 The test  l ine  and contro l  l ine 	11.1.2
 
Self-test	pregnancy	tests	usually	have	two	lines:	one	control	line	and	one	test	line	(Figure	4	A,	
B&C).	The	product	insert	is	recommended	to	include	information	on	exact	labeling	of	these	
lines	per	their	orientation.	Although	not	common	in	resource	poor	settings,	some	pregnancy	
tests	may	have	a	‘plus’	sign	or	the	word	‘positive’	if	positive	for	pregnancy.	
	
	
 Analytical and Diagnostic Performance of Self-Test Pregnancy Tests 11.2
	
The	specifications	and	test	panels	recommended	below	have	been	derived	from	
literature	reviews,	and	are	based	on	sound	scientific	evidence,	best	practices,	and	high	quality	
pregnancy	test	evaluations	(9,17-19).	Manufacturers’	inclusion	of	these	performance	metrics	in	
the	COA	or	Technical	Files	will	aid	the	decision-making	process	of	procurers.		
 11.2.1 Tar get  ant igen/ana lyte  
	
As	described	in	section	9,	the	pregnancy	tests	should	be	designed	to	identify	hCG	protein	in	
urine.	In	this	context,	hCG	protein	is	considered	as	the	antigen	or	analyte,	which	is	detected	and	
qualitatively	measured	by	the	test.	
 11.2.2 Reco mmended ana lyt ic al  sen si t iv i ty  (a lso  known  as detect ion  
l i mi t  or  cu t- of f )  
 
While	some	pregnancy	tests	are	more	or	less	sensitive	than	others,	it	is	recommended	to	
use	25	mIU/ml	as	the	criteria	for	analytical	sensitivity	(17-19);	98	%	of	women	who	conceive	
have	been	shown	to	have	25	mIU/ml	of	hCG	in	urine	on	the	first	day	after	the	missed	period.	If	
validated	clinical	evidence	exists,	the	manufacturer	may	state	the	number	of	days	after	the	
missed	period/menses	that	will	yield	a	positive	test	result	(US	FDA).			
	
 11.2.3  Reco mmended speci f ic i ty
 
It	is	strongly	recommended	that	the	manufacturer	state	the	outcomes	of	any	
specificity/cross-reactivity	testing	done	with	human	form	of	luteinizing	hormone	(hLH),	follicle	
stimulating	hormone	(hFSH)	and	thyroid	stimulating	hormone	(hTSH).	Recommended	
concentrations	for	testing	are:	hLH300-mIU/ml,	hFSH-1000	mIU/ml,	hTSH-1000	mIU/mL	(32).	
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Documents	for	Procurers:	It	is	recommended	that	procurers	request	
manufacturer’s	Certificate	of	Analysis	containing	technical	specifications	inclusive	
of	analytical	sensitivity	and	specificity.	If	the	Certificate	of	Analysis	does	not	contain	this	
information,	manufacturer	may	obtain	this	information	from	the	technical	files	and	
provide	them	in	a	format	that	is	easy	to	interpret.	
	
	
	
	
	
 Interfering	agents 11.2.4
Details of any substances that have been tested and shown to cause interference with 
test performance: 1) analyte-independent interferences caused by agents such as 
caffeine, glucose, hemoglobin, albumin, bilirubin and 2) analyte-dependent 
interferences/cross-reactivity caused by disease states, such as rheumatoid arthritis 
and syphilis, should be stated. Commonly used medications, such as pain relievers, 
antibiotics and contraceptives, should not interfere with test performance and 
evidence should be provided to support claims (9,10, 24).  
 Recommended	%	Accuracy 11.2.5
This value should not exceed 99%.  Statements such as ‘100% accurate, virtually 100% 
accurate, nearly 100% accurate,’ must always be proven by detailed clinical evidence 
(performance evaluation) (9) 
	
	
 Declared Reading  T ime and Stab i l i ty  of  Resu l ts  11.3
	
The	time	period	between	addition	of	urine	sample	to	reading	of	results	is	defined	as	the	‘declared	
reading	time’.	Depending	on	the	product,	this	time	typically	varies	(e.g.,	5,	10	or	15	minutes).	As	it	may	
not	be	possible	to	read	a	result	at	an	exact	moment,	especially	in	a	point	of	care	setting,	manufacturers	
may	provide	this	information	in	the	form	of	a	time	range,	as	in	minimum	time	to	results	and	maximum	
reading	time	or	as	a	recommended	reading	time.	Time	range	should	be	included	on	the	product	label	
and	in	the	package	insert.	
Upon	the	use	of	a	pregnancy	test,	the	test	and	control	lines	fade	and	change	in	intensity	over	time.	The	
rate	at	which	this	fading	takes	place	depends	on	the	product/manufacturer.	It	is	important	that	the	
manufacturer	displays	the	‘reading	window’,	which	is	the	time	range	within	which	the	test	results	should	
be	read,	on	the	product	label	and	in	the	package	insert.	While	there	is	some	overlap	between	declared	
reading	time	and	stability	of	results,	it	is	important	to	make	the	user	understand	that	beyond	a	certain	
time	limit,	the	results	should	not	be	read	or	interpreted.		
	
Enhanced	Quality	Practices	on	Test	Performance:	Include	a	list	of	interfering	agents	and	%	
accuracy	
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 Shel f -L i fe  11.4
	
Shelf-life	is	the	period	of	time,	during	which	the	test	in	its	original	packaging,	maintains	its	
performance	characteristics	under	the	storage	conditions	specified	by	the	manufacturer	
(WHO).	It	is	the	responsibility	of	the	manufacturer	to	ensure	that	all	claims	made	regarding	
shelf	life	are	supported	by	evidence.		It	is	recommended	that	manufactures	follow	ISO	236409	
when	designing	their	shelf-life	studies.		
• Recommended	storage	conditions	and	shelf	life	should	be	clearly	indicated	on	the	
product	label.	
• Pregnancy	tests	are	recommended	to	be	stable	for	storage	up	to	30°C,	with	stability	
claims	supported	by	evidence.		Although	submission	of	evidence	is	not	always	required	
by	SRAs,	the	US	FDA	requires	that	supporting	documents	remain	on	file	for	evaluation	
upon	request	(9).	Procurers	of	pregnancy	tests	are	encouraged	to	request	real-time	
experimental	stability	studies10	undertaken	on	batches	per	a	prescribed	protocol	from	
manufacturers	to	assess	heat	compatibility,	based	on	climate	conditions	of	the	region.	
Real	time	stability	should	be	conducted	over	a	period	longer	than	the	stated	shelf	life	of	
the	pregnancy	test.	
• Upon	receipt	by	the	procurer,	the	product	is	recommended	to	still	have	no	less	than	
5/6th	of	its	effective	life	(29).		
	
Documents	for	Procurers	on	Shelf-Life:	It	is	recommended	that	procurers	request	
evidence	of	real	time	experimental	stability	studies	indicating	evidence	for	heat	
stability	testing	of	the	pregnancy	test.	
	
	
	
	
	
	
						WHO	recommends	heat	stability	testing	at	35	°C	and	40	°C	for	MRDTs	as	these	tests	may	
be	subject	to	extreme	temperatures	during	transport.		Compromised	performance	of	some	
																																								 																				
9	Current	version	is	ISO	23640:2013	
10	Accelerated	stability	studies	are	usually	not	sufficient	to	support	a	shelf-life	claim	
	
Enhanced	Quality	Practices	for	Shelf-Life:	
A	Transport	Validation	Document	stating	minimum	and	maximum	transport	temperatures	
and	durations	should	be	made	available	
For	countries	that	experience	high	temperatures	and	humidity,	procurers	are	encouraged	to	
request	supporting	data	demonstrating	product	stability	up	to	35-40	°C	
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MRDT	products	exposed	to	high	temperatures	has	been	documented.	(28).	As	noted	earlier,	
the	assay	principle	for	MRDTs	and	pregnancy	tests	is	the	same.			It	is	recommended	that	
procurers	request	pregnancy	test	manufacturers	to	provide	supporting	documentation	to	
demonstrate	a	heat	stability	profile	within	this	recommended	range	if	applicable.		
	
	
 Packag ing  and K i t  Content11.5 	
	
Ø Primary	packaging	–	individually	sealed	pouches	containing	pregnancy	tests	(Figure	5A)	
Ø Secondary	packaging	–	a	unit	box	containing	defined	number	of	pregnancy	tests	(Figure	
5B)	
Figure	5:	Example	of	primary	and	secondary	packaging	
	
• Since	pregnancy	tests	can	be	sensitive	to	temperature	and	humidity,	primary	and	
secondary	packaging	should	ensure	their	protection	from	high	temperatures	and	
humidity	throughout	their	supply	chain	path	(i.e.,	from	manufacturing	site,	through	
transport,	storage	and	to	point-of-use.)		
• Based	on	WHO	recommendations	for	MRDTs	and	CE	guidelines	for	packaging,	addition	
of	desiccants	inside	primary	packaging	of	pregnancy	tests	is	strongly	recommended	to	
preserve	the	performance	of	the	test	(11).	Please	refer	to	Annex	S10	for	additional	
details.	
• 	
	
	
	
 Recommended Labeling Requirements for Secondary Packaging 11.6
(Cartons and Boxes) 
	
Enhanced	Quality	Practices	for	Packaging	and	Kit	Content:	Include	humidity-indicator	desiccant	
in	each	individual	test	pouch,	in	correct	packaging	with	adequate	labeling.	
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The	large	carton	containing	smaller	boxes,	as	well	as	the	smaller	boxes	containing	
pregnancy	tests,	are	recommended	to	have	the	label	information	listed	below.	Annex	S110	
provides	an	illustration	of	recommended	labeling	for	primary	and	secondary	packaging	using	
established	symbols	as	per	ISO	15223-1(ref).	
• Name	of	the	test		
• Batch/lot	number	
• Expiry	date		
• Name	and	address	of	manufacturer	(or	authorized	representative	if	applicable)	
• CE	marking	(if	applicable)	accompanied	by	identification	number	of	Notified	Body	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 Recommended Label ing  Requirements  for  Pr imary  Packag ing  11.7
and/or  Product  Insert   
	
Product	information	should	be	concise,	contain	clear	illustrations	and	be	easy	to	
understand.	In	developing	countries,	most	self-test	pregnancy	tests	have	this	information	
printed	directly	on	the	primary	packaging.	Inclusion	of	this	same	information	as	a	product	insert	
(printed	copy	inside	the	pouch)	is	a	slightly	costlier	alternative,	but	widely	practiced	in	the	
developed	world.		At	a	minimum,	the	following	label	information	is	recommended:	
• Legal	name	and	address	of	legal	manufacturer	(or,	if	applicable,	authorized	
representative)	
• Batch/lot	number	
• Expiry	date	
• CE	marking	(if	applicable)	accompanied	by	identification	number	of	Notified	Body	
• Intended	use	
Enhanced	Quality	Practices	for	Labeling	of	Secondary	Packaging:	
- Catalog	number	of	pregnancy	test	
- Date	of	manufacture	
- Recommendations	for	transport	and	storage:	keep	dry,	keep	away	from	
sunlight/heat	
- Clear	indication	of	in	vitro	diagnostic	status	
- Storage/handling	conditions	
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• Performance	characteristics:	analytical	sensitivity	and	specificity		
• Materials:	both	materials	provided	and	those	required	but	not	provided,	such	as	the	
urine	collection	cup	
• Product	support	contact	information	(i.e.	for	manufacturer	or	local	agent/marketing	
authorization	holder).	
• Step-by-step	instructions	from	collection	of	urine	sample	to	reading	the	results.	As	
indicated	in	Figure	6,	it	is	important	to	specify	time	period	required	for	each	of	the	4	
steps	of	the	test	procedure.	
o Step	1:	Time	to	keep	the	dipstick	immersed	in	urine,	or	if	using	a	midstream	test	
strip,	time	to	hold	the	dipstick	in	urine	stream	
o Step	2:	Time	to	test,	flat	on	a	surface,	for	the	results	to	develop.	Applicable	to	all	
3	tests	formats	
o Step	3:	Time	to	read	the	results	
Declared	reading	time	(the	time	from	adding	the	urine	sample	to	reading	the	
results;	details	in	section	11.3):		Minimum	time	to	reading	results	or	both	
minimum	and	maximum	time	to	reading	results	should	be	provided	by	the	
manufacturer.	Applicable	to	all	3	test	formats.	
o Step	4:	Time	beyond	which	test	results	should	not	be	read	
Since	the	stability	of	the	positive	lines	decrease	over	time,	results	should	not	be	
read	beyond	a	certain	time	(see	section	11.3	for	details).	It	is	recommended	that	
manufacturer	provide	this	time	beyond	which	the	results	are	not	stable.	
Applicable	to	all	3	test	formats.		
• Instructions	for	interpreting	results:	Figure	6	illustrates	four	possible	result	outcomes.		
Note:	the	exploratory	evaluation	of	pregnancy	tests	illustrated	that	‘invalid	results’	are	
commonly	represented	only	by	the	presence	of	test	line	turning	positive;	it	is	important	
to	include	the	other	invalid	result	option	of	a	blank	result	window,	which	is	indicative	of	
failure	of	either	the	performance	or	the	procedure	of	the	test	(Annex	S1).	
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Figure	6:	Example	of	instructions	for	use	and	result	interpretation	
	
	
	
	
	 Enhanced	Quality	Practices	for	primary	packaging	labeling	
requirements,	preferably	as	a	product	insert:	
- Description/summary	of	the	test	
- Principle	of	the	procedure	
- Description	of	the	procedural/reagent/sample	volume	
control	in	the	test		
- Limitations	of	the	procedure:	notice	that	the	test	cannot	
be	reused	and	should	not	be	used	past	the	expiration	
date;	health	conditions	that	can	cause	a	false	or	irregular	
results;	opportunities	for	false	negative	results;	
importance	of	adherence	to	instructions	for	use		
- Known	interfering	agents/results	from	studies	with	
interfering	agents	
- Instructions	for	use	in	national	language	(could	be	stapled	
on	to	the	primary	packaging)	
- Safe	use	and	disposal	information		
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12     Summary of Current, Recommended and Enhanced Quality 
Practices 
This	guidance	document	has	been	prepared	taking	into	consideration	potential	cost	constraints	
and	other	challenges	commonly	present	in	resource-poor	settings.	As	national	level	regulatory	
mechanisms	and	overall	healthcare	landscapes	continue	to	improve,	countries	may	apply	
increasingly	stringent	quality	review	standards	for	pregnancy	tests.	Figure	7	illustrates	currently	
prevalent	quality	practices,	recommendations,	and	enhanced	quality	practices.	The	
differentiation	between	recommendations	and	enhanced	quality	practices	were	made	through	
consensus	from	stakeholders.	
Figure	7:	Summary	of	current,	recommended	and	enhanced	quality	practices	relevant	to	
pregnancy	tests11	
	
																																								 																				
11	Please	refer	to	Annex	S10	for	definitions	of	the	symbols	
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13     Pre- and Post-Shipment Testing for Analytical Performance 
	
Goal:	to	develop	work	instructions	for	QA	of	specificity,	sensitivity,	accuracy,	and	package	seal	integrity		
Intended	audience:	any	laboratory	interested	in	evaluating	pregnancy	tests	(i.e.,	Africa,	Asia,	and	South	
America)	
Sources:	Information	obtained	from	publicly	available	sources,	and	not	from	proprietary	sources	(i.e.,	
manufacturers	/	suppliers)	
Content:	
Ø Sampling	plans	/	criteria	for	different	scenarios:						
Ø product	qualification		
Ø pre-shipment	testing	
Ø post-shipment	testing	
Ø stability	study	evaluations	
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15     Annexes 
 Annex  S1:  Exp loratory  ana lys is  o f  pregnancy  tests  purchased 15.1
from the deve loping  wor ld  to  ident i fy  preva i l ing  qua l i ty  gaps   
To	gain	a	preliminary	understanding	of	quality	status	of	pregnancy	tests	in	the	developing	
world,	an	in-house	assessment	of	16	pregnancy	tests	collected	over	a	2-year	period,	from	a	mix	
of	low-	and	middle-income	countries	in	the	African	region	was	carried	out.	These	pregnancy	
tests	were	purchased	from	pharmacies	as	individually	packaged	items.	These	tests	were	
benchmarked	against	27	relevant	criteria	compiled	from	normative	documents	that	have	been	
used	to	compile	this	guidance	document.		
Table	1:	Prevailing	quality	status	of	16	pregnancy	tests	from	developing	countries	
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 Annex S2: Quality approval of other Stringent Regulatory 15.2
Authorit ies (SRA) for consideration in the procurement of self-
test pregnancy tests 
SRA	is	a	regulatory	authority	(in	case	of	the	EU	both	EMEA	and	national	competent	authorities	are	
included)	which	is	(a)	a	member	of	the	International	Conference	on	Harmonization		of	Technical	
Requirements	for	Registration	of	Pharmaceuticals	for	Human	Use	ICH	(as	specified	on	its	
website:www.ich.org);	or	(b)	an	ICH	Observer,	being	the	European	Free	Trade	Association	(EFTA)	as	
represented	by	SwissMedic,	Health	Canada	and	WHO	(as	may	be	updated	from	time	to	time);	or	(c)	a	
regulatory	authority	associated	with	an	ICH	member	through	a	legally	binding	mutual	recognition	
agreement	including	Australia,	Norway,	Iceland	and	Liechtenstein	(as	may	be	updated	from	time	to	
time)	(33).	
Country	 	 Institution	 Website	
Australia	 	 Therapeutic	
Goods	
Administration	
https://www.tga.gov.au/	
	
Canada	 	 Health	Canada	 http://www.hc-sc.gc.ca/index-eng.php	
	
Europe	 	 European	
Medicines	
Agency12	
http://www.ema.europa.eu/ema/	
	
Iceland	 	 Iceland	Medicines	
Agency	
http://www.ima.is/ima/about_ima/	
	
Japan	 	 Pharmaceutical	
and	Medical	
Device	Agency	
https://www.pmda.go.jp/english/	
	
Norway	 	 Norwegian	
Medicines	Agency	
http://www.legemiddelverket.no/English/about-norwegian-
medicines-agency/Sider/default.aspx	
	
Switzerland	 	 Swiss	Agency	for	
Therapeutic	
Goods	
https://www.swissmedic.ch/index.html?lang=en	
	
United	
Kingdom	
	 Medicines	and	
Healthcare	
Products	
Regulatory	Agency	
(MHRA)	
	
https://www.gov.uk/government/organisations/medicines-and-
healthcare-products-regulatory-agency	
	
United	 	 Food	and	Drug	 http://www.fda.gov/	
																																								 																				
12	Includes	the	following	European	Member	States:	Belgium,	Bulgaria,	Cyprus,	Czech	Republic,	Denmark,	Estonia,	
Finland,	France,	Germany,	Greece,	Hungary,	Ireland,	Italy,	Latvia,	Lithuania,	Luxembourg,	Malta,	Poland,	Portugal,	
Romania,	Slovak	Republic,	Slovenia,	Spain,	Sweden,	The	Netherlands,	and	United	Kingdom	
For	links	to	individual	European	country	websites	please	refer	to	:	
https://www.ispor.org/HTARoadMaps/HealthAuthorityEurope.asp	and	https://www.pda.org/scientific-and-
regulatory-affairs/regulatory-resources/global-regulatory-authority-websites	
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States	 Administration	 	
	
 Annex S3: Checklist to be used for quality assurance of pregnancy tests 15.3
by procurers 
Procurers	may	use	this	checklist	to	verify	manufacturer’s	compliance	with	recommended	standards	
as	part	of	the	product	selection	process.	Items	shaded	in	green	are	those	listed	under	‘enhanced	
quality	practices’,	and	therefore,	are	recommended	to	adopt	as	the	country	regulatory	
infrastructure	improves	or	at	procurer’s	discretion	based	on	organizational	risk	analysis.	
Commercial	name	of	pregnancy	test	 	
Manufacturer	 	
Lot	number		 	
Date	of	assessment	 	
Name	of	assessor	 	
	 Yes	 No	 NA	 Comments/problems	
List	of	Documents	to	be	Provided	by	Manufacturer	
1. ISO	13485	certification	 	 	 	 	
2. CE	Declaration	of	Conformity	(if	
applicable)		
	 	 	 	
3. FDA	510	Clearance	Status	(if	applicable)		 	 	 	 	
4. Product	Stability	Documentation		 	 	 	 	
5. Certificate	of	Analysis		 	 	 	 	
6. Technical	File	 	 	 	 	
7. Test	results	from	independent	Quality	
Control	Tests	for	pre-	and	post-shipment	
testing	(if	applicable)	
	 	 	 	
Quality	Standards	
8. Manufacturer	compliant	with	ISO	
13485:______	
	 	 	 	
9. Compliant	with	a	different	standard	
(state	the	standard	under	comments)	
	 	 	 	
10. Product	is	CE	marked	 	 	 	 	
11. CE	mark	is	accompanied	by	the	
identification	number	of	the	notified	
body	
	 	 	 	
12. CE-marking	is	conformant		 	 	 	 	
13. Product	is	US	FDA	regulated	 	 	 	 	
14. Product	is	regulated	by	another	
Stringent	Regulatory	Authority	(state	
the	authority	in	the	comments	column)	
	 	 	 	
Labeling/Marking	on	Secondary	Packaging	(Carton	and	Boxes)	
15. Commercial	name	of	the	test	included	 	 	 	 	
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16. Batch/lot	number	included		 	 	 	 	
17. Expiry	date/shelf-life	included		 	 	 	 	
18. Name	and	address	of	manufacturer	
included		
	 	 	 	
19. Contact	details	of	a	‘local	authorized	
person’	included	(if	applicable)		
	 	 	 	
20. CE-marking	is	conformant		 	 	 	 	
21. Identification	number	of	notified	body	is	
present		
	 	 	 	
22. Catalog	number	included	 	 	 	 	
23. Manufacturing	date	included	 	 	 	 	
24. Storage/handling	conditions	are	
included	
	 	 	 	
25. Clear	indication	of	in	vitro	diagnostic	
status	included	
	 	 	 	
Packaging	and	Kit	Content	
26. The	secondary	packaging/box	containing	
tests,	is	in	good	condition	and	are	not	
torn,	wet	or	with	illegible	writing			
	 	 	 	
27. Pregnancy	tests	are	in	individually	
sealed	pouches	and	are	intact	
	 	 	 	
28. Shelf-life	indicated	on	the	product	label	 	 	 	 	
29. The	product	has	not	exceeded	1/6th	of	
its	effective	shelf-life	
	 	 	 	
30. The	tests	are	stable	up	to	30	°C	 	 	 	 	
31. Recommend	storage	conditions	
indicated	on	the	product	label	
	 	 	 	
32. The	tests	are	stable	up	to	40	°C	(if	
required	by	country	setting)	and	
supporting	documentation	is	available)		
	 	 	 	
Test	format	and	ancillary	items	
33. If	the	test	is	in	cassette	format:	
-The	control	and	test	lines	are	clearly	
marked	on	the	cassettes		
-A	device	for	transfer	of	urine	to	cassette	is	
included	
	 	 	 	
	 	 	 	
34. Desiccant	is	present	in	each	individually	
sealed	pouch	containing	a	pregnancy	
test	
	 	 	 	
35. Desiccant	is	packaged	in	material	that	is	
permeable	to	air		
	 	 	 	
36. Desiccant	packaging	has	adequate	
labeling		
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37. Desiccant	is	of	humidity-indicator	type	 	 	 	 	
Product	Information	for	Users/Product	Insert	
38. Product	information	is	included	
(printed	or	as	a	product	insert)	
	 	 	 	
39. The	product	information	is	for	the	
correct	product	
	 	 	 	
40. Instructions	for	use	is	provided	 	 	 	 	
41. Declared	reading	time	is	provided	(time	
to	read	results)	
	 	 	 	
42. Interpretation	of	results	is	explained	
with	illustrations	displaying	4	possible	
outcomes		
	 	 	 	
43. Materials	provided	and	materials	
required	but	not	provided	is	included		
	 	 	 	
44. Analytical	performance	information	is	
included	(sensitivity	and	specificity)	
	 	 	 	
45. Stated	analytical	sensitivity	is	25	
mIU/mL13	and/or	
46. Sensitivity	is	stated	in	number	of	days	
following	the	days	of	missed	
period/menses	
	 	 	 	
47. Specificity	results	indicated	(reactivity	
with	FSH,	TSH,	LH)	
	 	 	 	
48. Where	not	obvious,	intended	use,	‘for	
pregnancy	testing’,	is	clearly	indicated		
	 	 	 	
49. Local	product	support	contact	details	
included		
	 	 	 	
50. Additional	analytical	performance	info	
(accuracy	and	interfering	agents)	is	
included	
	 	 	 	
51. %	Accuracy	is	<99%		 	 	 	 	
52. Interference	substances	indicated	 	 	 	 	
53. A	summary	of	the	test	is	included		 	 	 	 	
54. Principle	of	the	procedure	is	included	 	 	 	 	
55. Quality	control	measures	are	included	 	 	 	 	
56. Product	information	is	in	national	
language	
	 	 	 	
57. Disposal	instructions	included	 	 	 	 	
58. Limitations	of	the	procedure	are	
included:	
	 	 	 	
	 	 	 	
																																								 																				
13	Several	studies	have	demonstrated	that	by	the	day	of	the	expected	period,	98%	of	women	who	have	conceived	
would	have	a	urinary	concentration	of	hCG	>	25	mIU/mL	(references).	
Ashini	Fernando	
PUBH	992:	Master’s	Paper	
63	|	P a g e 	
	
-The	test	cannot	be	reused	
-Do	not	use	past	the	expiration	date	
-Certain	health	conditions	can	cause	
false	positive	result	
-The	instructions	and	testing	procedure	
should	be	followed	precisely	for	
accurate	results	
-A	false	negative	result	could	result	if	
the	urine	is	too	dilute	or	with	very	early	
stage	pregnancy.	If	pregnancy	is	strongly	
suspected,	repeat	test	with	first-
morning	urine	
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 Annex  S4:  L i s t  o f  recommended procurement  gu idance  15.4
documents  on  procurement  process  and supply  cha in  
management  
	
	
1. A	Model	Quality	Assurance	System	For	Procurement	Agencies;	WHO,	UNICEF,	UNDP,	UNFPA	&	
World	Bank.	
	http://www.who.int/medicines/publications/ModelQualityAssurance.pdf	
	
2. Guidelines	for	the	Storage	of	Essential	Medicines	and	Health	Commodities;	
http://deliver.jsi.com/dlvr_content/resources/allpubs/guidelines/GuidStorEsse_Pock.pdf	
	
3. Guidelines	for	Warehousing	Health	Commodities,	USIAID	Deliver,	March	2014.		
http://deliver.jsi.com/dlvr_content/resources/allpubs/guidelines/GuidWareHealComm.pdf	
	
4. Managing	Access	to	Medicines	and	Health	Technologies	(MDS-3).	
http://www.msh.org/sites/msh.org/files/mds3-fm-revised-nov2012.pdf	
	
5. Manual	for	procurement	of	diagnostics	and	related	laboratory	items	and	equipment.	
http://www.who.int/diagnostics_laboratory/procurement/130627_manual_for_procurement_o
f_diagnostics-001-june2013.pdf	
	
6. Procurement	Capacity	Toolkit:	Tools	and	Resources	for	Procurement	of	Reproductive	Health	
Supplies,	PATH.			
http://www.path.org/publications/files/RH_proc_cap_toolkit_v2.pdf	
	
7. The	Logistics	Handbook:	A	Practical	Guide	for	the	Supply	Chain	Management	of	Health	
Commodities.	
https://www.k4health.org/sites/default/files/LogiHand_0.pdf	
www.deliver.jsi.com	
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 Annex  S5:  Contracept ive  Log is t ics  Cyc le  15.5
	
Illustrated	below	is	a	conceptual	framework,	adapted	by	The	Partnership	for	Maternal,	Newborn	and	
Child	Health,	for	contraceptive	supply	chain	management.	Improving	access	to	family	planning	requires	
a	robust	supply	chain	constituting	of	1)	Contraceptive	Product	Selection	2)	Quantification,	Forecasting	
and	Procurement	3)	Inventory	management	and	4)	Perioding	Evaluation,	with	continuous	monitoring	
(Rectangles	2-5).	These	components	should	strive	to	‘Serve	Client’	by	incorporating	the	“Six	Rights”:1)	
Right	Product	2)	Right	Quantity	3)	Right	Quality	4)	Right	Place	5)	Right	time	and	6)	Right	Cost	(Rectangle	
1).	
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 Annex S6: Assay principle of self-test pregnancy test 15.6
	
A.	Basic	architecture	of	a	pregnancy	test	strip:	a	typical	rapid	tests	consist	of	several	components	
adhered	to	an	inert	backing	2)	sample	pad	for	the	application	of	sample	2)	conjugate	pad	where	
dried	labeled	antibodies	are	deposited	3)	reaction	membrane	with	test	line	carrying	pregnancy	
specific	antibodies	and	a	control	line	carrying	antibodies	capable	of	recognizing	antibodies	4)	
wicking	pad	is	designed	to	draw	the	sample	across	the	reaction	membrane.	B.	Testing	with	urine:	
Upon	addition	of	urine,	the	liquid	moves	due	to	capillary	action,	hydrating	labeled	antibodies	and	
enabling	their	migration	across	the	membrane	towards	the	test	and	control	strips.	During	this	
process,	the	hCG	proteins	bind	the	labeled	antibodies	as	well	as	those	on	the	test	strip	as	they	are	
specific	for	hCG.	C.	Development	of	a	positive	result:	Recruitment	of	labeled	antibodies	to	the	
test	line	occurs	dependent	of	hCG,	and	the	accumulation	of	these	labeled	antibodies	result	in	the	
development	of	a	positive	line.	Recruitment	of	labeled	antibodies	to	the	control	line	is	
independent	of	hCG,	and	results	in	the	development	of	a	control	line	indicating	that	the	reagents	
and	the	assay	has	operated	as	expected.		
 Annex  S7.  Use  of  pregnancy  tests  in  fami ly  p lanning  for  15.7
opt imal  e f fect iveness  and ef f ic iency  
																Prior	to	initiation	of	hormonal	contraceptives	and	intra	uterine	devices	(IUD),	pregnancy	has	to	
be	ruled	out	to	avoid	possible	harm	to	the	fetus.	Family	planning	providers	currently	use	the	pregnancy	
checklist	and	pregnancy	tests	to	rule	out	pregnancy	among	clients	who	are	not	menstruating	at	the	time	
of	the	visit.	While	each	approach	has	its	advantages	and	limitations,	both	tools	have	to	be	used	under	
certain	circumstances	to	rule	out	pregnancy.	Currently,	as	there	is	no	guidance	on	the	usage	of	these	
tools	to	complement	one	another,	FHI	360	is	in	the	process	of	developing	a	protocol	to	rule	out	
pregnancy	in	three	mutually	exclusive	categories:	1)	Amenorrheic	(e.g.,	due	to	lactation	or	recent	use	of	
progesting-only	injectable	contraception)	2.	Between	menses	3)	has	missed	her	period.	
	
The	pregnancy	checklist	
This	job	aid	was	created	in	1990	by	FHI	360,	and	is	designed	to	rule	out	
pregnancy	with	six	simple	criteria	presented	in	question	form.	If	a	
woman	answers	‘yes’	to	any	of	the	six	questions,	then	pregnancy	can	be	
ruled	out	with	reasonable	degree	of	certainty.	It	is	important	to	note	
that	this	job	aid	cannot	be	used	to	rule	out	pregnancy	among	
amenorrheic	women.	
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 Annex S8: CE marking of conformity as specif ied in the 15.8
directive 98/79/EC of the European Parl iament and of the 
Counci l  
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 Annex S9: A Screenshot of FDA Premarket Notif ications (510(k) 15.9
clearance webpage that wil l  direct procurers to identify the 
510(k) clearance status of the pregnancy test being evaluated  
confirm	that	the	manufacturer	holds	510	(k)	clearance	by	visiting	the	510(k)	premarket	
notification	site		
(US	FDA	home	page	à	Medical	Devices	Tab	à	Medical	Device	Database	(under	Tools	&	
Resources)	à	select	the	‘Premarket	Notifications	(510(k)’	database	àtype	‘LCX’	under	
‘product	code’	à	Search	for	the	product	of	interest)	
Current	website	URL:	http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm	
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 Annex S10: Desiccants and their  recommended usage 15.10
Item	 Purpose	of	use/criteria	to	meet	 Recommendation	
Desiccant	
• Protects	the	test	from	exposure	to	humidity		
• Humidity	has	been	shown	to	decrease	
analytical	performance	of	RDTs	 Recommended	
Desiccant	with	humidity	
indicator	
• Indicates	if	the	desiccant,	and	therefore	the	
test,	was	exposed	to	humidity	
• Color	indicator	desiccant	is	preferred	over	
non-indicating	desiccants	
• Partial	indicators	are	difficult	to	view	for	
presence	of	humidity	
• Avoid	use	of	cobalt	dichloride	as	an	
indicator	due	to	demonstrated	adverse	
health	issues	
Enhanced	
quality	
practices	
Material	of	desiccant	
package	should	be	
permeable	to	air	
• Enables	uptake	of	humidity	by	desiccant	
• Avoid	use	of	sachets	with	plastic	packaging	
as	they	are	impenetrable	to	air	
• Paper-based	sachets	are	penetrable	to	air	
Recommended		
Sachet	with	desiccant	
should	be	transparent	or	
have	a	window	that	
allows	easy	visualization	
of	color	change	
• Aids	safe	and	easy	visualization	of	color	
change	in	desiccant	
	
Enhanced	
quality	
practice	
Warning	message	
indicating	not	to	eat	
desiccant	
• Desiccant	could	be	harmful	if	swallowed	
and	should	be	kept	away	from	children	
Recommended		
Sachet	with	desiccant	
should	carry	instructions	
for:	
interpretation	of	color	
changes	
- Steps	to	follow	if	test	
is	exposed	to	humidity	
- Safe	disposal	of	
desiccants	
• Enables	appropriate	decision	making	for	
accurate	and	safe	outcomes	
Enhanced	
quality	
practice	
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 Annex S11: Example of recommended label ing on primary 15.11
and secondary packaging (25,26) 
	
For	the	safe	and	effective	use	of	medical	devices,	ISO	15223-1:2012	has	identified	the	symbols	
used	below	for	use	in	labelling,	in	combination	with	applicable	ISO	standards.	This	information	
is	provided	as	a	source	of	information	for	interpreting	the	meanings	of	symbols	as	they	appear	
in	various	packaging,	as	well	as	enhanced	quality	practices	to	aspire	towards.	
	
	
 
